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Abstract 
Multiple Criteria Decision Analysis (MCDA) has emerged as a likely methodology for Health 
Technology Assessment (HTA). However limited empirical evidence is available on its use 
by decision-makers and only as part of single-setting exercises, without cross-county studies 
available. This pilot study applies the Advance Value Framework (AVF), an MCDA 
methodology for HTA based on multi-attribute value theory, through a series of case studies 
with decision-makers in four countries, to explore its feasibility and compare their value 
preferences and results. 
The AVF was applied in the evaluation of three drugs for metastatic, castrate resistant, 
prostate cancer (abiraterone, cabazitaxel and enzalutamide in the post-chemotherapy 
indication). Decision conferences were organised in four European countries in collaboration 
with their HTA or health insurance organisations by engaging relevant assessors and experts: 
Sweden (TLV), Andalusia/Spain (AETSA), Poland (AOTMiT) and Belgium (INAMI-
RIZIV). Participant value preferences, including performance scoring and criteria weighting, 
were elicited through a facilitated decision-analysis modelling approach using the 
MACBETH technique.  
Between 6 and 11 criteria were included in the value model of each country, allocated across 
four criteria domains; Therapeutic Benefit criteria conistently ranked first across countries in 
their relative importance. Consistent drug rankings were observed in all settings, with 
enzalutamide generating the highest overall weighted preference value (WPV) score, 
followed by abiraterone and cabazitaxel; dividing drugs’ overall WPV scores by their costs 
produced the lowest “cost-per-unit of value” for enzalutamide, followed for abiraterone and 
cabazitaxel. These results contrast the HTA recommendations and pricing decisions in real 
life.  
Overall, although some differences in value preferences were observed between countries, 
drug rankings remained the same. The MCDA methodology employed could act as a decision 
support tool in HTA, due to the transparency in the construction of value preferences in a 
collaborative manner.   
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Introduction 
In recent years, the introduction of new and costly health technologies, particularly in 
oncology, combined with moderate health gains, has sparked extensive debate on their value 
for patients and health care systems, how this value should be assessed and what should be 
the evaluation criteria informing coverage decisions (Cohen, 2017; Linley & Hughes, 2013). 
The debate has been fuelled by diverging coverage recommendations across settings for 
several medicines, often related to diseases associated with high morbidity and mortality 
(Clement et al., 2009; Faden et al., 2009; Nicod & Kanavos, 2012). Difference in opinion 
often arises in resource allocation decisions amongst different stakeholders, attributable, at 
least in part, to current evaluation methodologies not adequately capturing different notions of 
value (Drummond et al., 2013); this includes, for example, the Quality Adjusted Life Year 
(QALY), whose use in economic evaluations can at times be regarded as blunt and 
insufficient, among others, because it may not adequately reflect important value aspects in a 
variety of disease areas (Nancy Devlin & Lorgelly, 2017; Efthymiadou et al., 2019; Wouters 
et al., 2015). Given the limited consideration of value in traditional economic evaluations, 
additional parameters have been included in value assessments; however, this is often done in 
a non-systematic or ad-hoc manner, which may impact the transparency of decision-making 
processes (Angelis et al., 2018) and lead to inconsistencies in drug coverage decisions. 
A growing body of literature is increasingly debating the use of highly expensive new 
drugs, which are perceived to bring marginal added clinical benefit on the grounds of poor 
value-for-money and high budget impact (Nadler et al., 2006; Shih et al., 2013; Sulmasy & 
Moy, 2014). Rising drug prices and the need to understand the importance of different 
evaluation criteria have catalysed the generation of numerous “value frameworks” aiming to 
inform payers, clinicians and patients on the assessment of new medicines, required for 
making coverage and treatment selection decisions (Anderson et al., 2014; Bach, 2015; 
Cherny et al., 2015; Schnipper et al., 2015). Although this is an important step towards a more 
inclusive value-based assessment approach (Malone et al., 2016), aspects of these frameworks 
*Revised manuscript with tracked changes (EXCLUDING AUTHOR DETAILS)
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may be based on weak or ad hoc methodologies, which could potentially result in misleading 
recommendations or decisions (Angelis & Kanavos, 2016a).  
In response to some of the concerns raised above, multiple criteria decision analysis 
(MCDA) has emerged as an alternative to traditional economic evaluation techniques with the 
prospects of addressing some of their limitations in Health Technology Assessment (HTA) 
(Angelis et al., 2016; NJ Devlin & Sussex, 2011; Mireille M. Goetghebeur et al., 2008; 
Kanavos & Angelis, 2013; Marsh et al., 2014; Radaelli et al., 2014; J Sussex et al., 2013b; 
Thokala, 2011), but also for eliciting stakeholder preferences and faciltating treatment 
selection (Danner et al., 2011; Ijzerman et al., 2008; Tervonen et al., 2015). A number of 
MCDA empirical studies have explored the question of value in a number of therapeutic 
areas, often simulating hypothetical HTA settings (Angelis et al., 2017; M. M. Goetghebeur et 
al., 2010; Jon Sussex et al., 2013a; Wagner et al., 2017). However, very few studies have 
explored the same issue by eliciting the preferences of HTA agencies and sitting decision 
makers and only in single-case exercises  (Angelis, 2018; Jaramillo et al., 2016; Tony et al., 
2011). To the best of our knowledge, no study has ever compared the value preferences of 
decision-makers across multiple settings using a full MCDA methodology. 
By engaging HTA agencies and health insurance organisations in four EU Member 
States, we applied the Advance Value Framework (AVF), a recently developed multi-criteria 
value framework applicable to HTA (Angelis & Kanavos, 2016b; Angelis & Kanavos, 2017), 
to assess the value of a number of treatment options indicated for metastatic castrate resistant 
prostate cancer (mCRPC) following first line chemotherapy. This indication was selected 
because of its high disease burden and the availability of several new and expensive biologic 
drugs, making it a highly relevant appraisal topic for several HTA agencies. 
This is to our knowledge the first cross-country, complete MCDA pilot exercise, 
eliciting value preferences of sitting decision-makers from different HTA agencies for the 
same drug treatments while considering identical sets of evidence. The two main research 
questions of the study relate to testing the feasibility of this MCDA methodology for HTA 
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decision-makers, and to observing any differences in their value perceptions as reflected 
through the consistency of drugs’ value rankings, including value trade-offs.  
 
Methods 
Methodological Framework  
An MCDA approach based on Multi-Attribute Value Theory (MAVT) was adopted (Keeney 
& Raiffa, 1993; von Winterfeldt & Edwards, 1986), involving the phases of problem 
structuring, model building, model assessment, model appraisal, and development of action 
plans (Angelis & Kanavos, 2016b). A series of facilitated workshops were organised taking 
the form of decision conferences (Phillips, 2007), adopting a facilitated decision analysis 
modelling approach (Franco & Montibeller, 2010b; Phillips & Phillips, 1993), in 
collaboration with decision-makers from four HTA agencies and health insurance bodies: the 
Dental and Pharmaceutical Benefits Agency (TLV, Sweden), the Andalusian Health 
Technology Assessment Agency (AETSA, Spain), the Agency for Health Technology 
Assessment and Tariff System (AOTMiT, Poland), and the National Health Insurance Agency 
(INAMI-RIZIV, Belgium). The agencies in these countries were selected in order to represent 
a set of organisations with diferent governance structure (arms’ length HTA agency, e.g. 
AOTMiT, TLV and AETSA, vs integrated HTA function, e.g. INAMI-RIZIV) and 
responsibilities (regulatory, e.g. TLV, vs advisory AOTMiT and AETSA). This research was 
undertaken in the context of Advance-HTA, an EU-funded project focusing on HTA 
methodological advancements (London School of Economics, 2019), and all four HTA 
organisations were contacted to participate under the auspices of the project. 
The methodological process used in terms of the design, implementation and analysis, 
is aligned with the ISPOR good practice guidelines on the use of MCDA for health care 
decisions (Marsh et al., 2016).  
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Problem structuring: Clinical Practice and Scope of the Exercise  
Prostate cancer is the second most commonly diagnosed cancer in men globally and the most 
frequently diagnosed cancer among men in developed countries; it is the fifth leading cause of 
cancer death globally (Torre, 2015). Death rates have been decreasing in the majority of 
developed countries, which has mainly been attributed to improved treatment and/or early 
detection (Center et al., 2012). 
The decision context relates to the assessment of value of second line treatments for 
mCRPC based on the approved European Medicines Agency (EMA) indication (EMA, 
2016a, b, c), the subsequently defined scope of Technology Appraisals (TAs) by a number of 
HTA agencies and the ESMO guidelines (Horwich et al., 2013; NICE, 2012a, b, 2014; TLV, 
2014, 2015a).     
The first treatment to demonstrate a survival benefit for mCRPC patients was 
docetaxel chemotherapy in combination with prednisolone when compared to mitoxantrone in 
combination with prednisolone (Berthold et al., 2008; Tannock et al., 2004). Subsequently, 
new therapeutic agents have been tested in the post-chemotherapy setting with considerable 
success. Abiraterone, a steroid synthesis inhibitor, in combination with prednisolone showed a 
3.9-month improvement in survival compared to prednisolone alone in patients pre-treated 
with docetaxel (14.8 vs 10.9 months, HR 0.65, p<0.001) (de Bono et al., 2011). Similarly, 
enzalutamide, an androgen receptor antagonist, showed a 4.8-month improvement in survival 
(18.4 vs 13.6 months, HR 0.63, p<0.001) compared to placebo alone in the same patient 
group (Scher et al., 2012). Cross-resistance appears to exist between abiraterone and 
enzalutamide meaning that patients are unlikely to derive clinical benefit by switching from 
one to the other agent (Bianchini et al., 2014; Loriot et al., 2013). The third agent that is 
widely used following progression on docetaxel is cabazitaxel, a taxane chemotherapy. 
Cabazitaxel led to an overall survival (OS) benefit of 2.4 months (15.1 vs 12.7 months, HR 
0.70, p<0.0001) compared to mitoxantrone (de Bono et al., 2010). Given this therapeutic 
landscape for patients with mCRPC who have progressed on first line docetaxel 
chemotherapy, characterised by an availability of different treatments and the apparent cross-
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resistance between some of them, we adopt post-chemotherapy mCRPC as the decision 
context for the application of the AVF methodology.  
 
Model Building: Advance Value Tree adaptation, treatments compared and reference levels 
The model building phase comprised a number of tasks, notably the Advance Value Tree 
adaptation for mCRPC, the consideration of alternative drug treatments and the respective 
evidence, and the definition of criteria attributes and the associated ranges, all of which are 
discussed below. Detailed discussion on the rationale of each criterion and their value scales 
can be found elsewhere (Angelis & Kanavos, 2017; Angelis et al., 2017).  
 
(a) Adaptation of the Advance Value Tree for Metastatic Prostate Cancer  
At the core of AVF lies the Advance Value Tree, a hierarchical structure of evaluation criteria 
taking the form of a generic value tree reflecting value concerns of HTA experts and decision-
makers for new medicines (Angelis & Kanavos, 2017). The Advance Value Tree consists of 
five criteria domains, aiming to capture the essential value attributes of new medicines in the 
HTA context under a prescriptive decision-aid approach. These are divided into (a) Burden of 
Disease (BoD); (b) Therapeutic Benefit (THE); (c) Safety Profile (SAF); (d) Innovation Level 
(INN); and (e) Socioeconomic Impact (SOC), summarised by the following value function:  
  
                                 (1) 
 
The Advance Value Tree was adapted into a disease-specific mCRPC value model using a 
bottom-up approach by comparing the characteristics of the specific drugs evaluated (Franco 
& Montibeller, 2010a). In consultation with a specialist medical oncologist (co-author of the 
paper), the generic evaluation criteria were converted into disease-specific criteria, while 
adhering to required criteria properties such as non-redundancy and preferential-independence 
(Keeney, 1992), to ensure methodological robustness and an adequate value model rooted in 
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decision theory. Based on the above, a preliminary mCRPC-specific value tree was produced 
with four criteria domains and a total of 18 criteria, each operationalised by an attribute, i.e. 
performance indicator, as shown in Figure 1. The BoD domain was not considered in the 
adaptation process on the grounds of conciseness, as all drugs were indicated for the same 
indication which would have identical BoD. 
Criteria definitions (together with their consideration in each jurisdiction and their 
rankings) are provided in Table 1.  The preliminary version of the mCRPC value tree was 
subsequently validated by decision conference participants, in line with a “socio-technical” 
approach, a constructive decision-aid process allowing groups of participants to interact with 
and learn from each other (Bana e Costa & Beinat, 2005).  
 
<Figure 1 about here> 
 
(b)  Alternative Treatments Compared and Evidence Considered  
The alternative drug options assessed in the exercise were cabazitaxel in combination with 
prednisolone, abiraterone in combination with prednisolone and enzalutamide monotherapy.  
The key evidence sources used to assess their performance included (a) the peer review 
publications concerning the pivotal clinical trials of the alternative treatment options that were 
considered for their licencing by the EMA (de Bono et al., 2011; de Bono et al., 2010; Fizazi 
et al., 2012; Scher et al., 2012); (b) the Product Information sections of EMA’s European 
Public Assessment Reports (EPAR) (Annex I and III) (EMA, 2016a, b, c); (c) the Anatomical 
Therapeutic Chemical (ATC) classification system indexes available through the portal of the 
WHO Collaborating Centre for Drug Statistics Methodology (World Health Organisation 
Collaborating Centre, 2016); and (d) the US National Library of Medicine clinical trials 
database (NIH, 2016). Additional sources of evidence included national sources (BNF, 2015; 
Connock et al., 2011; NICE, 2012a, b, 2014; Riemsa et al., 2013) and other peer review 
literature (Burström et al., 2001; Collins et al., 2007; Kearns et al., 2013; Sullivan et al., 
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2007), which was relevant to the study indication. Sources of evidence used relating to the 
performance of drugs across evaluation criteria are shown in Appendix Table A1, alongside 
additional information on the evidence considered. 
 
(c) Options Performance and References Levels  
By considering the performance of the alternative drug options across the value scales, 
“lower” (x_l) and “higher” (x_h) reference levels were defined to serve as benchmarks for the 
value scores of 0 and 100 respectively, acting as value anchors for constructing value 
functions and eliciting their relative weights (Bana e Costa & Vansnick, 1999; Keeney, 1982). 
The “lower” reference levels denoted a less preferred state reflecting a “satisfactory” 
performance level, whereas the “higher” reference levels denoted a more preferred state 
reflecting an “ideal” performance level.  
The reference levels for the clinical attributes informing the Therapeutic and Safety 
criteria domains, were defined in consultation with the clinical oncologist (co-author of the 
paper). In principle, the rationale involved adopting the Best Supportive Care (BSC) 
performance as a “satisfactory” reference level, with a hypothetical 20% improvement of the 
best available performance acting as the “ideal” reference level (e.g. ‘overall survival’), or, 
alternatively, the best possible limit of the performance scale acting as an “ideal” level in 
cases where this was naturally restricted (e.g. ‘treatment discontinuation’). The 20% 
hypothetical performance improvement was selected because it was perceived to be a 
realistically plausible scenario for future treatment options. By considering the performance 
of best available option(s) among the treatments evaluated and accounting for plausible 
performance improvement in the near future, the value scale essentially reflected 
characteristics of a “global” scale to account for the performance of future options not 
captured in the exercise, i.e. what is best plausible (Belton & Stewart, 2002). Where a BSC 
performance was not meaningful to act as a “lower” reference level, then the lowest (i.e. 
worst) possible limit of the performance scale was adopted (e.g. ‘Phase 3’), or, alternatively, 
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20% lower than the lowest performing option was used (e.g. ‘medical costs impact’). An 
exception to the above was the ‘health related quality of life’ (HRQoL) attribute for which the 
stable disease state’s utility score was adopted as the “lower” level and the general population 
utility score was used as the “higher” level. 
The emerging partial value function scores of the drugs for each criterion can take 
negative values or values higher than 100 where v(xlower) = 0 and v(xhigher) = 100, essentially 
by conducting a positive linear transformation.  “Lower” and “higher” reference levels for all 
attributes at the pre-decision conference stage and the basis of their selection are outlined in 
Appendix Table A2. A matrix listing the performance of drug options across the final 
attributes that were considered in the decision conferences, together with their reference 
levels, is shown in Table 2. 
 
Model Assessment and Appraisal: Decision conferences, MCDA technique and cost 
calculation 
The model assessment and appraisal phases comprised the tasks of conducting the decision 
conferences, the application of the MCDA technique for the elicitation of value preferences 
and cost calculation(s). These are discussed below. 
 
(a) Decision conferences 
Model assessment and model appraisal took place through a series of decision conferences 
(Phillips, 2007), taking the form of facilitated workshops with the participation of decision-
makers, including assessors and national experts, all of whom were affiliated with the four 
study HTA organisations, either as members of staff or visiting external experts (their 
difference being in full-time employment versus part-time or visiting capacity employment). 
For the purposes of this study, they were both regarded as “decision-makers”, given their 
influence on methodological development within the agencies and on the decision outcomes 
of the appraisals. Across the four countries, between four (for the case of TLV) and 13 (for 
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the case of AOTMiT) participants were involved, typically comprising health care 
professionals (clinicians, pharmacists), HTA methodology experts (health economists, 
statisticians, HTA agency directors) and decision-makers (members of HTA appraisal 
committees, representatives from insurance funds and the national medicines agencies). 
Background material introducing the scope of the exercise in more detail was sent to the 
participants one week before each decision conference. Decision conferences were hosted at 
the head offices of the different HTA organisations between June 2015 and April 2016: 
Stockholm (TLV), Seville (AETSA), Warsaw (AOTMiT), and Brussels (INAMI-RIZIV).  
The lead author acted as an impartial facilitator, assisted the groups’ interactions and 
guided participants through the decision problem using the preliminary version of the 
mCRPC-specific value tree (Figure 1) and the relevant data. This acted as the model’s starting 
point, based on which value judgements and preferences were elicited at the start of each 
decision conference while seeking group interaction and agreement (Franco & Montibeller, 
2010b; Phillips, 1984; Phillips & Bana e Costa, 2007; Schein, 1999). The Appendix provides 
more information on the decision conferences.  
 
(b) MCDA Technique 
AVF adopts a value measurement MCDA methodology making use of a simple additive (i.e. 
linear, weighted average) value model for the aggregation of scores and weights (Angelis & 
Kanavos, 2017). This assumes preference independence between the different criteria, with 
overall value V(.) of an option a defined by the equation below (Keeney, 1992; von 
Winterfeldt & Edwards, 1986): 
 
                                                        (2) 
 
Where m is the number of evaluation criteria, wi vi(a) is the weighted partial value function of 
evaluation criterion i for treatment a, and V(a) is the overall value of a treatment a. V(.) is 
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therefore is an overall value function based on multi-attribute value theory (Keeney & Raiffa, 
1993).  
A value function associated with each attribute, converting the treatment performance 
on the attribute range to a value scale, was elicited from the participants during the decision 
conferences using the Measuring Attractiveness by a Categorical Based Evaluation Technique 
(MACBETH) questioning protocol and the M-MACBETH software (Bana e Costa & 
Vansnick, 1999). This protocol requires pairwise comparisons where qualitative judgements 
about the difference of value between different pairs of attribute levels (i.e. difference in value 
between x and y units on a criterion) are expressed using seven qualitative categories (i.e. no 
difference, very weak difference, weak difference, moderate difference, strong difference, 
very strong difference, or extreme difference) (Bana E Costa et al., 2012; Bana e Costa & 
Vansnick, 1994). MACBETH provides a constructive and user-friendly approach to generate 
a cardinal (interval) value scale based on the input of these qualitative pair-wise judgements, 
which are then converted into value scores via an optimization algorithm (Bana e Costa et al., 
2016b); this approach has been widely used as a decision support tool (Bana e Costa et al., 
2014; Bana e Costa et al., 2002; Bana e Costa & Oliveira, 2012; Bana e Costa & Vansnick, 
1997). 
Weights for a multi-attribute value function should be elicited considering the range 
of each attribute and the value of a “swing” between two reference levels. The weights are 
scaling constants that convert partial value scores into overall value scores that must reflect 
value trade-offs and, therefore, should not be interpreted as measurements of ‘direct 
importance’. An indirect (qualitative) swing weighting technique was applied to elicit relative 
criteria weights by first ordering the swings of each attribute and then valuing their 
differences using the MACBETH qualitative categories (Bana E Costa et al., 2012). 
The above MACBETH-based scoring and weighting techniques were operationalised 
using the software M-MACBETH, (Bana e Costa & Vansnick, 1999). The software automates 
the additive aggregation of preference value scores and weights in order to derive overall 
weighted preference value (WPV) scores and also allows for sensitivity analysis on the 
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criteria weights. The software also enables the use of visual graphics to build a model of 
values, acting as a facilitation tool to inform both the design and the evaluation phases of the 
methodological framework (Bana e Costa et al., 2016a; Bana e Costa & Vansnick, 1999; 
Bana e Costa et al., 1999). More information regarding the technical details of MACBETH is 
available in the Appendix. 
 
(c) Cost Calculation 
UK list prices at ex-factory level were used as found in BNF (BNF, 2015) as a neutral 
benchmark in order to allow the measurement of cost(s) in a common unit across all study 
settings, so that overall WPV scores can then be viewed against the same cost denominator to 
produce comparable cost-value ratios. Access to confidential prices through risk sharing 
agreements was not possible. Information on the recommended dosages and treatment 
durations were sourced from the peer review publications of the pivotal trials and respective 
EPARs from EMA (de Bono et al., 2011; de Bono et al., 2010; EMA, 2016a, b, c; Scher et al., 
2012). Drug administration costs for cabazitaxel were kept consistent with the respective 
NICE TA (NICE, 2012b), whereas for abiraterone and enzaluatmide these costs were not 
applicable as they are orally administered.   
 
Results 
Final Value Trees, Options Performance, Criteria Weights and Value Functions 
Across the four countries, decision conferences were characterised by increased interaction 
and extensive debate between participants, especially in cases where there was disagreement 
about certain values. Because the majority of participants had a shared understanding of the 
decision problem but also a sense of common purpose and commitment to way forward, all of 
which are conditions for good practice in decision conferencing, the deliberative process of 
each decision conference instigated a fruitful discussion and exchange of views around 
different criteria values and relative importance.  
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General consensus was reached among participants in terms of criteria consideration 
and model validation with no major value aspects deemed to be missing. All attributes 
included in each country’s final mCRPC value tree, as emerged following open interaction 
with decision conference participants and their rankings, are shown in Table 1 (schematic 
illustrations of the individual value trees are shown in Appendix Figure A1). The main reason 
for not including a criterion attribute in the value tree was because participants considerted it 
was non-fundamental for the evaluation, in all cases of which a zero weight was assigned. 
Most of the criteria attributes that were assigned a zero weight belonged in the Innovation 
Level domain, which comprised the highest number of criteria.  
 
<Table 1 about here> 
 
The performance of the drug options across the different attributes that were 
considered to be fundamental in the model (i.e. weight greater than zero) together with the 
“lower” and “higher” reference levels are shown in Table 2.  
 
<Table 2 about here> 
 
Between 6 (AOTMiT) and 11 (AETSA/INAMI) criteria attributes were included in 
the final value tree of each country, as shown in Table 3. In terms of the different criteria 
domains composition, the Therapeutic Benefit contained between two 
(TLV/AOTMiT/INAMI) and three (AETSA) criteria attributes, the Safety Profile between 
one (AOTMiT) and two (TLV/AETSA/INAMI), the Innovation Level between two 
(TLV/AOTMiT) and six (INAMI), and the Socioeconomic Impact always one.  
 
<Table 3 about here> 
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During the elicitation of the ‘overall survival’ (OS) and/or ‘HRQoL’ criteria value 
functions, it became evident that these criteria attributes might be preference dependent. 
When asking participants to judge the difference in value between different increments in 
attribute performance (either in ‘OS’ or ‘HRQoL’), a request for clarification was raised by 
some of them relating to what level of performance this change was associated with on the 
other criterion attribute. In order to address the plausible preference-dependence observed, we 
combined together the two attributes in an aggregated form. The two criteria attributes were 
combined by multiplying the number of months in ‘OS’ and their EQ-5D utility scores in 
‘HRQoL’ attributes respectively, assuming an equal (i.e. 50%) distribution of stable and 
progressive disease states, essentially deriving quality adjusted life months (QALMs). An 
example of a MACBETH value judgements matrix and its conversion into a value function 
for the case of the ‘OS x HRQoL’ aggregated criterion attribute in QALMs is shown in 
Appendix Figure A2.  
There was a common set of six criteria that were considered as fundamental in all 
countries: (a)  ‘OS x HRQoL’; (b) ‘radiographic tumour progression’ (also known as 
progression free survival (PFS); (c) ‘treatment discontinuation’; (d) ‘delivery posology’; (e) 
‘special instructions’; and (f) ‘medical costs impact’. This common set of criteria comprised 
the complete set of TLV’s value tree (n=6), whereas AOTMIT’s value tree considered 
‘contraindications’ in addition (n=7). Further to these, AETSA’s value tree also considered 
‘PSA response’, ‘ATCL4’, ‘Phase 3’ and ‘marketing authorisation’ (n=11), whereas INAMI’s 
value tree considered the same additional criteria but with ‘Phase 2’ instead of ‘PSA 
response’ (n=11). 
Overall, the different groups of decision conferences’ participants agreed in the 
valuation of performance for the six common attributes that were considered across all four 
countries, as revealed through the elicitation of their value functions. Figure 2 plots the value 
scores of each drug across the six common attributes showing very similar valuations between 
countries.   
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<Figure 2 about here> 
 
The weights of relative importance assigned to the different attributes across the four 
jurisdictions are shown in Figure 3. By taking into account the relative swings of the criteria 
attributes, i.e. the gap between the “lower” and “higher” reference levels, quantitative weights 
were derived for each attribute using M-MACBETH. The ‘OS x HRQoL’ aggregated 
criterion attribute was always assigned the highest relative weight out of 100 ([31,44] for 
INAMI and AETSA, respectively), followed either by ‘treatment discontinuation’ ([17,21] for 
AETSA and TLV, respectively) or ‘medical costs impact’ ([20,30] for INAMI and AOTMiT, 
respectively). Depending on the country, the third-ranked criterion was then either ‘treatment 
discontinuation’ (AOTMiT, INAMI), ‘medical costs impact’ (TLV), or ‘contraindications’ 
(AETSA) and ‘PFS’ was ranked 4th or 5th. ‘Special instructions’, although a fundamental 
criterion across settings, was ranked in the lowest place in 3 out of 4 settings with the 
‘delivery posology’ usually at a higher position, with the exception of TLV where that order 
was reversed. 
 
<Figure 3 about here> 
 
In terms of the total weights assigned across the different criteria domains, the 
Therapeutic Benefit weight ranged from 40% to 54% (for AOTMiT/ INAMI and AETSA, 
respectively), the Safety Profile weight ranged from 20% to 33% (for AOTMiT and TLV, 
respectively), the Innovation Level weight ranged from 7% to 13% (for TLV and INAMI, 
respectively) and the Socioeconomic Impact weight ranged from 8% to 30% (for AETSA and 
AOTMiT, respectively) (Table 3). The above differences in relative weights reflect the 
different priorities of decision-makers, including the number of fundamental objectives being 
considered. 
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Overall Drug Rankings and Value-for-Money Analysis 
With regards to the overall WPV scores shown in Table 4,  enzalutamide consistently yielded 
the highest score across all four countries, always followed by abiraterone and cabazitaxel. 
The overall scores of abiraterone and cabazitaxel were in part influenced by a “negative” 
performance in the ‘treatment discontinuation’ attribute (19% and 18% respectively) which 
lay below the lower reference level of the scale (i.e. 10%), affecting negatively their overall 
value scores.  
A stacked bar plot of the drugs’ overall WPV scores across all settings is shown in 
Figure 4. By using rounded up cost figures for enzalutamide (£24,600), abiraterone (£21,900) 
and cabazitaxel (£23,900, of which £22,190 related to drug cost and the remainder £1,710 to 
administration cost) and dividing them with overall WPV scores, their costs per MCDA value 
unit ranged as follows: (a) enzalutamide: £410 - £501 (for AOTMiT and AETSA, 
respectively); (b) abiraterone: £1,366 - £9,221 (for INAMI and TLV, respectively); and (c) 
cabazitaxel: £2,196 - £6,816 (for INAMI and AOTMiT, respectively) (Table 4).  The overall 
value score of each option was driven by the fundamental objectives considered (i.e. criteria 
influencing the model), the criteria weights which were anchored on reference levels, and the 
shape of value functions which would influence the value scores. 
 
<Table 4 about here> 
 
<Figure 4 about here> 
 
In terms of value-for-money, cabazitaxel was shown to be dominated by abiraterone, 
and was very close to being dominated by enzalutamide (i.e. a difference of £500 based on the 
prices used). Enzalutamide on the other hand was associated with a higher cost (a difference 
of £2,500 based on the prices used) and a higher overall WPV score compared to abiraterone, 
with a difference in score ranging between 40.4 to 52.7 value units (for AETSA and TLV, 
respectively). Cost benefit plots of the different options, using their overall WPV scores 
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versus their purchasing (plus any administration) costs across the four HTA organisations is 
shown in Figure 5.   
 
<Figure 5 about here> 
 
Similarities and differences in value perceptions across settings 
By looking at Table 3 (and Figure 3) of the results, a number of similarities and differences in 
value preferences are observed across the four settings. The largest number of evaluation 
criteria were considered in Andalusia and Belgium (11 each), compared to Sweden and 
Poland (7 and 6, respectively), partly due to a higher number of Innovation Level criteria (5 
and 6, compared to 2 each, respectively). In terms of the relative importance of criteria 
domains, the Therapeutic Benefit cluster consistently ranked first across all settings. The 
Safety Profile cluster was ranked second in three settings (except for Poland, where the 
Socioeconomic Impact cluster ranked higher (30% vs 20%)). The Socioeconomic Impact 
cluster ranked 3rd in Sweden and Belgium but 4th in Andalusia (8%). Finally, the Innovation 
Level cluster ranked 4th in three countries with the exception of Andalusia where it ranked 3rd 
(12%). The low relative importance of the Innovation Level cluster partly justifies why a 
hypothetical change in the final consideration of Innovation Level criteria across the different 
countries does not influence the ranking of the treatments, as described in the next section.  
Despite the observed differences in evaluation criteria considered, the relative criteria 
weights assigned and the elicited value functions, the overall ranking of the treatments 
remained identical across countries (Table 4 and Figure 4) with enzalutamide consistently 
having the highest score, followed by abiraterone and cabazitaxel in all fours settings. 
 
Sensitivity and Robustness Analysis 
Following each decision conference, deterministic sensitivity analysis was conducted to 
address parameter uncertainty on criteria weights. Specifically, changes on baseline weights 
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were explored to check their possible impact on treatments’ overall value rankings. The 
results of the sensitivity analysis demonstrated that the ranking of the treatments was robust to 
the relative criteria weights across the different settings.    
The most sensitive criterion weight, which could change enzalutamide’s ranking 
order from first to second, was ‘PFS’ in the cases of INAMI and AETSA where a 10.2 and 
11.1 times change (from 8.9% to 90.6% and from 8.0% to 88.5%) respectively, would be 
required for cabazitaxel to rank first and enzalutamide second. In other words, a higher than 
10-times difference on the ‘PFS’ weight would be required for cabazitaxel to outperform 
enzalutamide, with changes of higher order required in other criteria weights for either 
cabazitaxel or abiraterone to rank first, in any of the study settings. Criteria weights were 
more sensitive with regards to the outperformance of abiraterone by cabazitaxel as the 
second-best treatment. Again, the most sensitive weight was for ‘PFS’ in the INAMI and 
AETSA cases, where a 2-times change (from 8.9% to 17.4% and from 8.0% to 16.7% 
respectively) would be needed for cabazitaxel to rank second and abiraterone third. This 
meant that the lowest change across criteria weights needed for an impact on treatment 
rankings to be observed was for the case of PFS with INAMI, where at least a 2-time 
difference was required for abiraterone to be outperformed. For the case of TLV and 
AOTMiT, the most sensitive criterion was treatment discontinuation in which a 2.6 and 3.0 
times change would be needed (from 21.2% to 54.6% and from 20% to 60% respectively) for 
cabazitaxel to rank second-best.  
The final consideration of the Innovation Level criteria cluster was explored in 
greater detail given that their relevance might be disputed. Removing the ‘ATCL4’ criterion 
and any spill-over effect criteria (i.e. ‘Phase-2’, ‘Phase-3’, ‘MA’) from the value tree of 
AETSA and INAMI, and any patient convenience criteria (i.e. ‘delivery posology’, ‘special 
instructions’) from all country value trees would not affect the treatment rankings.  
 
18 
 
Discussion and policy implications 
This study is the first comparative MCDA exercise, utilising the Advance Value Framework 
and engaging sitting HTA decicion-makers across four EU Member States to elicit and 
comprare their preferences in the evaluation of three mCRPC treatments. In doing so, the 
objective was to test the usefulness feasibility of MCDA methods for HTA decision-makers 
and identify differences in value perceptions.   
Based on the evidence used, our results showed that the most valuable therapy for second line 
mCRPC was enzalutamide, followed by abiraterone and cabazitaxel. Each treatment was 
assessed and ranked based on their overall WPV scores, reflecting the value of their 
performance against a set of evaluation criteria, weighted against their relative importance. 
These overall scores were based on the value preferences of decision-makers that were 
collected via a decision conference in each setting, yielding a comprehensive and transparent, 
multi-dimensional benefit component. Subsequent consideration of drug costs (purchasing 
and administration) enabled the estimation of value-for-money in the form of “cost-per-unit of 
value” ratios which showed the second-ranked treatment (abiraterone) to dominate the third 
(cabazitaxel).  
It should be noted that the constructed benefit metric excludes the cost of the 
treatments, i.e. the WPV score considers the impact of the technology on medical costs other 
than the purchasing cost of the technology. Therefore, evaluation of the treatments based 
solely on their overall WPV scores might not be appropriately designed to inform an HTA 
decision context that considers the interventions’ incremental cost per incremental benefit, 
but, rather, a value-based approach to reimbursement or pricing negotiation. 
Attempting a comparison of the ranking achieved in this exercise with what has taken 
place in reality might prove challenging, partly because of how the clinical evidence was 
treated in the exercise, but also because it is not publicly known whether and how any of the 
additional value dimensions evaluated in the exercise were considered in the relevant HTA 
decision-making processes. In Sweden, although abiraterone’s ICER vs BSC (manufacturer 
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estimate of SEK820,000/QALY)(TLV, 2015a), was lower compared to enzalutamide’s ICER 
vs BSC (TLV best estimate of SEK1,100,000/QALY)(TLV, 2014), or lower vs enzalutamide 
(SEK800,000/QALY)(TLV, 2015b), TLV assumed that both treatments had the same clinical 
effect and consequently focused on a cost-minimisation approach rather than cost-utility 
analysis, leading to the implementation of a confidential risk sharing agreement (RSA) as part 
of which discounts can be provided based on treatment duration. A similar conclusion was 
reached in Spain, where the Ministry of Health in its Clinical Assessment Report (Informe de 
Posicionamento Terapeutico - IPT) recommended that there is no clinically relevant 
difference between the benefit-risk balance of enzalutamide and abiraterone, and, therefore, 
decisions should be guided based on drug costs (AEMPS, 2015). Pricing and reimbursement 
decisions are then taken by the Interministerial Committee for Pricing and Reimbursement, 
but the final assessment is not publicly available. At regional/hospital level, a group of 
hospital pharmacists conducted a full health (clinical and economic) technology assessment, 
where enzalutamide and abiraterone were considered to be therapeutically equivalent 
(GHEMA, 2016). In Poland, although AOTMiT accepted that some additional clinical effect 
existed for enzalutamide compared to abiraterone (mainly in secondary endpoints), it was not 
found to be cost-effective compared to abiraterone; however, a confidential RSA enabled a 
final positive recommendation by AOTMiT (AOTMiT, 2017). The final decision 
implemented by the Ministry of Health was to reimburse enzalutamide, similarly to the case 
of abiraterone (Obwieszczenie, 2017). In Belgium, following an indirect comparison no 
clinically relevant differences were found in the treatment outcomes of abiraterone versus 
enzalutamide (INAMI, 2019);  eventually, a managed entry agreement (MEA) enabled 
reimbursement.   
Consequently, and based on the evidence used to populate the MCDA model and 
which would inform decision-making, the hypothetical coverage decisions emerging from the 
ranking of the treatments based on their overall WPV scores might have been different. Given 
the higher overall value of enzalutamide compared to abiraterone, a cost minimisation 
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approach or price parity attained between the two, as inferred following the risk sharing 
agreements in place, might not have been justified. 
One reason why our value models make slightly different predictions is because it has 
captured benefits that go beyond the current formal remits of HTA agencies, therefore the 
results should be viewed as ‘proof-of-concept’, for the purposes of testing the performance of 
the methodology.  Furthermore, the decision context addressed in the exercise was a one-off 
evaluation problem within the indication of mCRPC which might contradict the operational 
scope of some HTA agencies and health insurance bodies relating to repeated decisions 
around the reimbursement of drugs across different disease areas.  
The extent to which HTA decision-makers can be relied upon, or not, to reflect 
societal preferences when constructing their value preferences is a very important topic for 
discussion but not aimed to be addressed in this study. Here, we simply elicited decision-
makers’ own preferences without considering whether these might be representative for 
society or not. In reality, evidence in Belgium suggests that health care coverage related 
preferences of decision-makers differ to those of the public (Cleemput et al., 2018), and 
therefore more research would be needed to reveal such discrepancies.   
Overall, the HTA decision-makers that participated in the decision conferences 
provided positive feedback about the potential usefulness of the value framework and the 
MCDA approach in general, raising the prospects of the framework acting as a decision 
support tool in the evaluation of new medicines. According to participants, key advantages of 
the framework included the feasibility to transparently assess the performance of the options 
across a number of explicit evaluation criteria, while allowing the elicitation of value trade-
offs (i.e. their relative importance), and its overall facilitative nature in the construction and 
analysis of group value preferences. Our results are in line with past evidence on a different 
oncology indication (Angelis et al., 2017). 
 
Challenges of MCDA applications in HTA 
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The assessment across 4 settings has offered a number of important insights relating to the 
application of MCDA in HTA and the challenges this represents. In order for any MCDA 
methodology to become a useful tool for HTA decision-makers and serve their needs, certain 
requirements must be met: first, sound methods should be used to ensure technical 
requirements are fulfilled (Keeney & Raiffa, 1993); second, social aspects of the process 
should be treated carefully to ensure various socio-technical requirements are fulfilled 
(Baltussen et al., 2017); and, third, tools and guidelines should be available and tailored for 
the appropriate audience ensuring that best practice requirements are fulfilled (Phillips, 2017).   
Among the first group of technical requirements, one key challenge of MCDA studies 
in HTA relates to the theoretical properties that are required for the evaluation criteria. Due to 
the popularity of using a simple additive (i.e. weighted average) value model, the violation of 
preference-independence is of particular relevance as it might undermine the validity of such 
models and the insights offered by the results (Marsh et al., 2018; Morton, 2017). Evidence 
suggests that preference dependencies might exist between health gain and disease severity 
(Nord et al., 2009), or between OS and HRQoL (Angelis & Kanavos, 2017). The latter also 
featured strongly in this study, where such a preference dependence between OS and HRQoL 
was detected during the decision conferences and, as a result, the two criteria attributes were 
combined into a common aggregated attribute. Beyond combining the two criteria into a 
common aggregated attribute, other more technically complex solutions exist for addressing 
preference dependencies, such as using other functional forms of aggregation for combining 
scores and weights together, such as multiplicative models (Chongtrakul et al., 2005). 
Furthermore, tests for identifying preference dependencies have existed for many years 
(Currim & Sarin, 1984; Keeney, 1992; Rodrigues et al., 2017). 
Other technical challenges relate to the need for evaluation criteria to be non-
overlapping so that there can be no double counting, and that criteria weights are connected to 
the attribute ranges. If either one of these conditions is not satisfied, criteria weights could 
misrepresent decision makers’ true value preferences. Furthermore, a number of cognitive 
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biases may affect value judgments and thus appropriate elicitation protocols and de-biasing 
tools must be employed (Montibeller & Winterfeldt, 2015).    
In order to avoid double-counting, a clear justification of their inclusion is needed, 
which should be on the grounds of addressing the fundamental objectives of the analysis, 
rather than be informed based on the existence of available evidence and data (Keeney, 1992; 
Keeney & Gregory, 2005).  This process could be supported by the use of problem structuring 
tools aiming to distinguish between ‘fundamental objectives’ and ‘means objectives’ (Franco 
& Montibeller, 2010a), as we adopted in this exercise.  
In terms of weighting, asking direct questions for the general importance of criteria 
are known to be one of the most common mistakes when eliciting value trade-offs (Keeney, 
1992; Keeney, 2002). Instead, sound weighting procedures for the assignment of relative 
weights should take place in accordance with the use of explicit lower and higher reference 
levels (Belton & Stewart, 2002; Keeney, 2002), ideally through user-friendly indirect 
technique protocols that can reduce bias, similar to what we aimed for in this exercise through 
the explicit definition of reference levels and the implementation of the qualitative 
(MACBETH) swing weighting technique.   
A further challenge relates to the linking of MCDA results with coverage and 
resource allocation decisions, possibly through the use of specific value thresholds, that can 
reflect the efficiency and opportunity cost of funding decisions (Sculpher et al., 2017). In 
economic evaluation, incremental cost effectiveness ratio (ICER) thresholds are supposed to 
reflect the opportunity cost of the benefit foregone elsewhere in the health care system that 
would have resulted from the coverage of alternative technologies (Claxton et al., 2015).  
Assuming that a QALY-based ICER threshold is accurate, it could be used as a benchmark to 
create an MCDA value threshold by extrapolating the ICER threshold in proportion to how 
much of the MCDA model’s weight is accounted for by non-QALY value components 
(Phelps & Madhavan, 2018). Alternatively, following the generation of a multi-dimensional 
benefit component, purchasing costs could be used to derive treatments’ cost-value ratios to 
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inform the resource allocation decisions assuming a fixed budget (Peacock et al., 2007), 
similar to our approach in this exercise with the calculation of the “cost per unit of value”.  
 
Study limitations  
The study has a number of limitations, both related to the clinical evidence used and the 
MCDA process followed, so results should be interpreted with caution. First, in terms of the 
clinical data used, there was a lack of relative treatment effects; in order to counteract that, 
absolute treatment effects from different clinical trials were used based on the assumption that 
they are directly comparable which might not be accurate even for similar patient populations 
in the studies. As a result, differences in the performance of the options that have been valued 
might in reality not be statistical significant, e.g. in OS. Ideally, one would need indirect 
comparisons or a network meta-analysis (NMA) through a mixed treatment comparison 
(Jansen et al., 2011), therefore, an evidence synthesis step would be required as part of the 
model-building phase; as, for example, in the case of assessing the comparative benefit-risk of 
statins in primary prevention (Tervonen et al., 2015) or second-generation antidepressants 
(van Valkenhoef et al., 2012).  
Second, another clinical evidence related limitation could be that only the treatments’ 
impact on HRQoL of the stable disease state was assessed, because no treatment was assumed 
to have any effect during progression (NICE, 2014). This might not be true for other disease 
indications in which case the relevant HRQoL attribute would have to capture both the stable 
and progressive disease states. 
Third, there are also a number of limitations in terms of the MCDA process adopted: 
one of them relates to the relatively small number of participants in some decision 
conferences, which could reflect a limited representation of perspectives for the purpose of 
informing policy-making. A group size of between seven and 15 participants is known to be 
ideal as they are large enough to represent all major perspectives but small enough to work 
towards agreement, effectively allowing for efficient group processes to emerge while 
preserving individuality, (Phillips & Phillips, 1993).  However, capturing an all-round set of 
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preferences was not among the primary aims of the exercise. The value scale of the treatment 
discontinuation attribute and, more specifically, the “lower” reference level of “10%” could 
be perceived as a limitation because it influenced the negative partial value scores of two 
treatments whose performance was worse. This was the outcome of consultation with an 
oncologist, based on evidence from one of the clinical trials’ placebo-contolled arms, because 
it was believed to better resemble BSC used in practice; although others might have chosen a 
different performance level to define the “lower” reference level, the overall ranking of the 
treatments did not change when altering the lowest reference level to a much less preferred 
hypothetical performance (20% lower than the worst performing option), while keeping the 
weights constant.  
One major advantage in MCDA, is that it can be tailormade to reflect decision-
makers’ needs, by taking into account different fundamental objectives through the 
consideration of a variety of criteria, reflecting their priorities (by eliciting relative weights) 
and representing their preferences (by eliciting value functions). However, it should be 
recognised that the emerging differences that have been described above, prevent the direct 
comparison of overall value scores for alternative options; these would require identical value 
trees (i.e. the same set of criteria, weights and value functions across settings), in addition to 
the same evidence on options performance. The ranking comparisons that we have made in 
this study using ordinal scales reflect these limitations.  
 
Conclusions and implications  
In this study, we tested the application of AVF, a multi-criteria value framework, in 
collaboration with HTA decision-makers in order to deduce its feasibility and compare results 
across settings, in an effort to investigate its potential usefulness and limitations for the 
purposes of HTA. We found that the AVF methodology can act as a valuable decision support 
tool because of the transparent construction of value preferences in a collaborative manner, 
which facilitates the evaluation processes of groups, including the elicitation of value 
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preferences and trade-offs. Although we observed setting-specific differences in value 
perceptions, the rankings of drugs remained consistent across all countries. Based on the 
evidence used in the exercise, a coverage decision using this method would have pointed 
towards a different recommendation denoting differences in value between the first two 
treatments, in contrast with the cost minimisation approach adopted or the price parity 
attained between the two in real life.  
Despite a number of limitations relating to data and process issues and the existence 
of broader challenges with the use of MCDA in HTA due to specific methodological 
requirements which would need to be satisfied, the present study has demonstrated that an 
MCDA framework can, in fact, provide meaningful valuations of novel health technologies 
which, in turn, can inform coverage decisions.  
The MCDA methodology adopted enabled participants in the study countries to 
reflect on certain value dimensions and incorporate these more explicitly in the deliberation 
process, supporting its use as a transparent value communication tool. Future research efforts 
could involve similar cross-county case studies, the advancement of MCDA methods and 
their alignment with HTA policy needs, or repeating the study with different participants to 
understand whether similarities and differences identified in this study can be replicated.  
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Appendix  
 
Model Building: Alternative Treatments Compared and Evidence Considered  
The source of evidence used for identifying the performance of options across the evaluation 
criteria is shown in Table A1.  
 
Model Building: Setting Attribute Ranges and Reference Levels 
For the case of clinical therapeutic attributes, “lower” reference levels were based on best 
standard of care (BSC) performance, coming from the median of the respective placebo arm 
of the AFFIRM trial, with the exception of the HRQoL attribute (EQ-5D utility score) that 
was based on the utility of stable disease with no treatment coming from past NICE TAs 
(NICE, 2012a, b). The “higher” reference levels were derived by adding a 20% absolute 
improvement to the performance level of the best performing option, besides for the case of 
the HRQoL attribute (EQ-5D utility score) that was based on the general Swedish population 
(Burström et al., 2001). The rationale was to design a value scale incorporating a “global” 
reference level (Belton & Stewart, 2002), reflecting an “ideal” performance (as proxied by the 
20% improvement in best available performance), corresponding to the 100 anchor level of 
the value scale. This could also offer a flexibility margin to be able to incorporate the 
performance of future improved options within the same elicited value scale. Consequently, 
two reference levels within the attribute range were defined in most cases: i) the “lower” 
reference level (x_l) (i.e. BSC-based satisfactory performance), acting on the same time also 
as the minimum limit of the attribute range (x_*); and ii) the “higher” reference level (x_h) 
(i.e. 20% better than the best performing option), acting on the same time as the maximum 
limit of the attribute range (x^*) to give x_*=x_l ≤ x_h= x^*.  
A similar, but reverse, logic was used for setting the reference levels in the “treatment 
discontinuation” attribute of the safety cluster; the “lower” reference level was defined to be 
equal to the BSC (i.e. placebo) arm of the AFFIRM trial. However, contrary to the logic 
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adopted so far for the therapeutic benefit criteria, the “higher” reference level was not set 
equal to 20% worse than the best performing option (because the lower the performance, the 
higher the value), but rather equal to the minimum, i.e. worst possible, natural limit of the 
attribute scale (i.e. 0%) which was regarded as an “ideal” level. In turn, the minimum limit of 
the scale was derived by worsening the performance of the worst performing treatment option 
by 20%. A similar approach was used for setting the reference levels of the qualitative 
“contraindications” attribute, defining the “higher” reference level  equal to the maximum 
(i.e. most attractive) limit of the attribute scale (i.e. none known contraindications) and the 
“lower” reference level equal to the minimum (i.e. least attractive) limit of the attribute scale.  
For the innovation attributes, the “higher” reference level was set either equal to 20% 
better than the best performing option for the case of natural quantitative attributes (e.g. 
number of new indications for which the technology is investigated in a given clinical 
development stage), or equal to the maximum, i.e. best possible, limit of the scale for the case 
of constructed qualitative attributes (e.g. the existence of any special instructions, the 
technology's relative market entrance in regards to its ATC Level), reflecting a “global” 
versus “local” scaling approach respectively. Given that the BSC performance was irrelevant 
to be used as satisfactory level in the innovation attributes, and any efforts to derive a 
“satisfactory” level would be subjective in nature, the minimum limit of the scale for each 
attribute was used as a “lower” reference level. Therefore the “lower” reference level was 
based on the worst performance plausible as inferred from the lowest possible limit of the 
scales, both for the case of natural quantitative attributes (e.g. 0 number of new indications for 
which the technology is investigated in a given clinical development stage), and the case of 
constructed qualitative attributes (e.g. worst possible combination of special instructions, 5th 
entrance at an ATC level).  
For the socioeconomics attribute (impact on direct costs), the “higher” reference level 
was based on the BSC’s impact on cost (i.e. £0 impact on costs), given that by definition 
impact on costs for all treatment options are incremental to BSC, and the “lower” reference 
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level was derived by adding a 20% absolute increment to the worst performing option (i.e. to 
the one with the biggest impact on costs).  
 “Lower” and “higher” reference levels for all attributes at the pre-workshop stage 
and the basis of their selection are outlined in Table A2 (assuming no impact of luteinizing 
hormone-releasing hormone analogue).  
 
Model Assessment and Appraisal: Decision Conference 
On the day of each decision conference the preliminary model was validated with the 
participants by revising it cluster by cluster through an open discussion, seeking group 
consensus and adopting an iterative and interactive-model-building process where debate was 
encouraged and differences of opinion were actively sought.  
In terms of the decision-aiding methodology used, the lead author acted as an 
impartial facilitator with the aim of enhancing content and process interaction, while 
refraining from contributing to the content of the group’s discussions, essentially guiding the 
group in how to think about the issues but not what to think (Phillips & Bana e Costa, 2007; 
Schein, 1999).  
In terms of facilities, the rooms of the decision conferences had a Π-shaped meeting 
table for all the participants to have direct eye to eye contact, with an overhead projector 
screen and a second protable projector or large TV screen. The M-MACBETH software 
(more information provided in the MCDA Technique section of the main text and below) was 
operated using a laptop, the screen of which was connected to the projector, and the second 
screen was used to show the list of the evaluation criteria together with their “lower” and 
“higher” reference levels. 
The decision conferences took place over a full working day or two half working 
days; in the former case, there was one lunch break and two coffee breaks throughout the day, 
whereas in the latter case only a coffee break took place around the middle of each session. In 
each decision conference, the day started with an overview of the MCDA methodology 
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adopted and the description of the preliminary version of the value tree which was then 
analysed cluster by cluster. At the beginning of each cluster the value tree was validated; the 
various criteria were explained, followed by a group discussion relating to their relevance and 
completeness. As a result of this iterative process, some of the criteria were not included 
because they were perceived as irrelevant or non-fundamental. Schematic illustrations of the 
final versions of the value trees are shown in Figure A1. Then, value functions were elicited 
for the different criteria and relative weights were assigned within the clusters. Finally, 
relative weights were assigned across clusters, enabling the calculation of the options’ overall 
WPV scores.  
 
Model Assessment and Appraisal: MCDA Technique 
MACBETH uses seven semantic categories ranging between “no difference” to “extreme 
difference”, in order to distinguish between the value of different attribute levels. Based on 
these qualitative judgements of difference and, by analysing judgmental inconsistencies, it 
facilitates the move from ordinal preference modeling, a cognitively less demanding 
elicitation of preferences, to a quantitative value function. The approach has evolved through 
the course of theoretical research and real world practical applications, making it an 
interactive decision support system that facilitates decision-makers’ communication. An 
example of the type of questioning being asked would be “What do you judge to be the 
difference of value between x’ and x’’?” where x’ and x’’ are two different attribute levels of 
attribute x, across the plausible range (i.e. x* ≤ x’, x’’ ≤ x*). The value judgements matrix for 
the Overall Survival attribute and their conversion into its value function is provided as an 
example in Figure A2.  
Following the elicitation of value functions, criteria baseline weights can be elicited. 
Questions of direct importance for a criterion such as “How important is a given criterion?” 
are known to be as one of the most common mistakes when making value trade-offs because 
they are assessing them independent of the respective attribute ranges (Keeney, 2002). In 
contrast, indirect weighting technique that assess value trade-offs in tandem with the 
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respective ranges of attributes should be employed. For example, the quantitative swing 
weighting technique asks for judgments of relative value between ‘swings’ (i.e. changes from 
standard lower level x* to higher reference level x* on each xth attribute) taking the form “How 
would you rank the relative importance of the criteria, considering their attributes ranges 
relative to 100 for the highest-ranked criterion considering its range?”. Each swing, i.e. a 
relative change from a lower attribute level to a higher attribute level, is valued between 0 and 
100, with the most valuable swing anchored as 100 (von Winterfeldt & Edwards, 1986). 
Normalised weights are then calculated, as a proportion of each swing weight, so the 
normalised weights summed to 100%. Instead, relative attribute weights were calculated 
using an alternative qualitative swing weighting protocol, by using the MACBETH procedure 
to elicit the differences in attractiveness between the lower and higher reference levels of the 
different attributes, initially at individual level and then at criteria cluster level (i.e. by 
considering multiple attribute swings on the same time) (Bana e Costa et al., 2016b; Bana E 
Costa et al., 2012). 
Finally criteria preference value scores and the respective weights can be combined 
together through an additive aggregation approach as described in equation 2 (if the adequate 
conditions of complete and transitive preferences are met as well as multi-attribute 
preferential independence conditions (von Winterfeldt & Edwards, 1986)).   
The M-MACBETH software automatically performs consistency checking between 
the qualitative judgements expressed, and in addition a second consistency check was 
manually performed by the author to validate the cardinality, i.e. interval nature, of the 
emerging value scale. This was done by comparing the sizes of the intervals between the 
proposed scores and inviting participants to adjust them if necessary (Fasolo & Bana e Costa, 
2014), a requirement which is essential for the application of simple additive value models. 
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Table 1: Criteria definitions, their consideration in each jurisdiction and their ranking  
Criteria Sub-
Domain 
Evaluation 
criteria  
Definition 
Country (competent HTA organisation) 
Belgium 
(INAMI/RIZIV) 
 
Poland 
(AOTMiT) 
Andalusia 
(AETSA) 
Sweden 
(TLV) 
Criteria Domain 1: Therapeutic Benefit 
Direct endpoints 
Overall survival x 
Health related quality 
of life* 
The median time from treatment randomisation to 
death adjusted for the mean health related quality 
of life using the EQ-5D utility score  
(1st) (1st) (1st) (1st) 
Indirect endpoints 
Radiographic tumour 
progression 
The median survival time on which patients have not 
experienced disease progression (using RECIST 
criteria) 
(5th) (5th) (4th) (5th) 
PSA response 
The proportion of patients having a ≥50% reduction 
in PSA     
(8th)  
Criteria Domain 2: Safety Profile 
Tolerability 
Treatment 
discontinuation 
The proportion of patients discontinuing treatment 
due to adverse events 
(3rd) (3rd) (2nd) (2nd) 
Contra-indications & 
warnings 
Contra-indications 
The existence of any type of contra-indication 
accompanying the treatment 
(4th)  (3rd) (4th) 
Criteria Domain 3: Innovation Level 
Type and timing of 
innovation 
ATC Level 1 
The technology's relative market entrance in regards 
to its ATC Level 1 (Anatomical) 
    
ATC Level 2 
The technology's relative market entrance in regards 
to its ATC Level 2 (Therapeutic) 
    
ATC Level 3 
The technology's relative market entrance in regards 
to its ATC Level 3 (Pharmacological) 
    
ATC Level 4 
The technology's relative market entrance in regards 
to its ATC Level 4 (Chemical) 
(6th)  (10th)  
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ATC Level 5 
The technology's relative market entrance in regards 
to its ATC  Level 5 (Molecular) 
    
Spill-over effect 
Phase 1 
The number of new indications for which the 
technology is investigated in  Phase 1 clinical trials 
    
Phase 2 
The number of new indications for which the 
technology is investigated in  Phase 2 clinical trials 
(8th)    
Phase 3 
The number of new indications for which the 
technology is investigated in  Phase 2 clinical trials 
(9th)  (9th)  
Marketing 
authorisation 
The number of new indications that the technology 
has gained an approval for at the stage of marketing 
authorisation 
(10th)  (7th)  
Patient convenience 
Delivery posology 
The combination of the delivery system (RoA and 
dosage form) with the posology (frequency of dosing 
and duration of administration) of the treatment 
(7th) (4th) (6th) (7th) 
Special instructions 
The existence of any special instructions 
accompanying the administration of the treatment 
(11th) (6th) (11th) (6th) 
Criteria Domain 4: Socio-Economic Impact 
 
 
Direct costs 
Medical costs impact 
The impact of the technology on direct medical costs 
excluding the purchasing costs of the technology 
(2nd) (2nd) (5th) (3rd) 
Notes: *: Aggregation between OS and HRQoL criteria took place due to preference-dependence leading to a combined criterion; PSA= prostate-specific 
antigen; ATC=Anatomical Therapeutic Chemical classification system; RoA=Route of Administration. 
Source: The authors, based on DCs in Andalusia/Spain, Belgium, Poland and Sweden. 
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Table 2: Performance matrix and reference levels considered across the final criteria attributes  
Criterion name Attribute metric Lower level Abiraterone Cabazitaxel Enzalutamide Higher level 
Overall survival (OS)* Months 13.6 15.8 15.1 18.4 22.1 
Health Related Quality of Life 
(HRQoL), stable disease* 
Utility (EQ-5D) 0.72 0.76 0.76*** 0.76 0.82 
Health Related Quality of Life 
(HRQoL), progressive disease* 
Utility (EQ-5D) 0.64 0.64 0.64 0.64 0.82 
OS X HRQoL** 
Quality adjusted life 
months (QALMs) 
9.2 11 10.5 12.8 18.1 
Radiographic tumour progression, 
i.e. progression free survival (PFS) 
 
Months 2.9 5.6 8.8 8.3 10.6 
PSA response % of patients 1.5 29.5 39.2 54 64.8 
Treatment discontinuation 
 
% of patients 10 19 18 8 0 
Contra-indication(s) 
Type of contra- 
indication 
hyp + hep imp + 
low neut 
hyp + hep imp 
hyp + hep imp + 
low neut 
hyp None 
ATC Level 4, i.e. chemical 
mechanism of action 
Relative market entrance 5
th
 2
nd
 2
nd
 1
st
 1
st
 
Phase 2 Number of new indications 0 1 13 4 16 
Phase 3 Number of new indications 0 1 2 0 2 
Marketing authorisation Number of new indications 0 0 0 0 1 
Delivery posology 
Type of delivery system & 
posology combinations 
Oral, daily - one 
off + IV, every 3 
weeks - 1 hr 
Oral,  
daily - one off 
Oral, daily - one 
off + IV, every 3 
weeks - 1 hr 
Oral,  
daily - one off 
Oral,  
daily - one off 
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Special instructions 
Type(s) of special 
instructions 
Concomitant 
and/or pre- med 
+ no food 
Concomitant 
and/or pre- 
med + no food 
Concomitant 
and/or pre- med  
None None 
Medical costs impact 
 
GBP 10,000 5,750 7,992 567 0 
Notes: * Used for the calculation of the quality adjusted life months (QALMs) attribute of the aggregated OS x HRQoL criterion; ** Calculated assuming an 
equal 50% split in time duration between the stable disease and progressive disease states in HRQoL; *** Used the same score of the other two options as 
data not available; hyp = hypersensitivity; hep imp = hepatic impairment; low neut = low neutrophil count.  
Source: The authors from the literature. 
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Table 3: Number of criteria attributes per cluster, relative weights per criteria cluster and their ranking across the four HTA settings. 
 
  
Sweden  
(TLV) 
Andalusia  
(AETSA) 
Poland 
 (AOTMiT) 
Belgium 
 (INAMI-RIZIV) 
HTA Agency/  
Criteria Clusters 
Criteria 
numbers 
Criteria 
weights 
Criteria 
ranking 
Criteria 
numbers 
Criteria 
weights 
Criteria 
ranking 
Criteria 
numbers 
Criteria 
weights 
Criteria 
ranking 
Criteria 
numbers 
Criteria 
weights 
Criteria 
ranking 
Therapeutic Benefit 2 44.5 1
st
  3 54.3 1
st
 2 40.0 1
st
 2 40.0 1
st
 
Safety Profile 2 33.3 2
nd
 2 26.0 2
nd
 1 20.0 3
rd
 2 26.7 2
nd
 
Innovation Level 2 7.4 4
th
 5 11.8 3
rd
 2 10.0 4
th
 6 13.3 4
th
 
Socioeconomic Impact 1 14.8 3
rd
 1 7.9 4
th
 1 30.0 2
nd
 1 20.0 3
rd
 
Total 7 100   11 100   6 100   11 100   
 
Source: The authors based on input from decision conferences. 
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Table 4: Overall weighted preference value (WPV) scores, costs and costs per unit of value across the four HTA settings.  
 
Treatments/  
HTA agency 
Enzalutamide Abiraterone Cabazitaxel 
  
Overall WPV 
score 
Ranking per 
country 
Overall WPV 
score 
Ranking per 
country 
Overall WPV 
score 
Ranking per 
country 
Sweden (TLV) 55.1 1
st
  2.4 2
nd
  -3.4 3
rd
  
Andalusia (AETSA) 49.1 1
st
  8.8 2
nd
  4.4 3
rd
  
Poland (AOTMiT) 59.9 1
st
  12.1 2
nd
  3.5 3
rd
  
Belgium (INAMI-RIZIV) 58.6 1
st
  16.0 2
nd
  10.9 3
rd
  
Costs (£) 24,600 21,900 23,900 
  
Cost per unit 
of value 
Ranking per 
country 
Cost per unit of 
value 
Ranking per 
country 
Cost per unit of 
value 
Ranking per 
country 
Sweden (TLV) 447 1
st
  9,221 2
nd
  N/A 3
rd
  
Andalusia (AETSA) 501 1
st
  2,496 2
nd
  5,481 3
rd
  
Poland (AOTMiT) 410 1
st
  1,805 2
nd
  6,816 3
rd
  
Belgium (INAMI-RIZIV) 420 1
st
  1,366 2
nd
  2,196 3
rd
  
  
Note: No cost-per-unit of value was calculated because of the negative overall WPV score (i.e. having a worst overall performance compared to the 
performance of the lower reference level), which would produce a negative cost-per-unit of value (£23,900/(-3.4) = -7,072) and would therefore faulty 
“improve” the median figure of the treatment.   
Source: The authors. 
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Figure 1: Preliminary value tree for metastatic prostate cancer (pre-workshop). 
 
 
 
 
Notes: Contra. = Contraindications; MoA = Mechanism of action; HRQoL = Health related quality of 
life; PSA = Prostate-specific Antigen; ATC = Anatomical therapeutic chemical; Image produced using 
the Hiview3 software version 3.2.0.4. 
Source: The authors. 
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Figure 2: Criteria valuation drug profiles. 
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Figure 3: Relative criteria weights stacked bars across the four HTA settings. 
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Figure 4: Stacked bar plot of treatments’ overall weighted preference value scores across the four HTA settings. 
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Figure 5: Cost benefit plots of treatments overall weighted preference value scores versus their purchasing costs across the four HTA settings 
(TLV top left, AETSA top right, AOTMiT, bottom left, INAMI bottom right). 
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Introduction 
In recent years, the introduction of new and costly health technologies, particularly in 
oncology, combined with moderate health gains, has sparked extensive debate on their value 
for patients and health care systems, how this value should be assessed and what should be 
the evaluation criteria informing coverage decisions (Cohen, 2017; Linley & Hughes, 2013). 
The debate has been fuelled by diverging coverage recommendations across settings for 
several medicines, often related to diseases associated with high morbidity and mortality 
(Clement et al., 2009; Faden et al., 2009; Nicod & Kanavos, 2012). Difference in opinion 
often arises in resource allocation decisions amongst different stakeholders, attributable, at 
least in part, to current evaluation methodologies not adequately capturing different notions of 
value (Drummond et al., 2013); this includes, for example, the Quality Adjusted Life Year 
(QALY), whose use in economic evaluations can at times be regarded as blunt and 
insufficient, among others, because it may not adequately reflect important value aspects in a 
variety of disease areas (Nancy Devlin & Lorgelly, 2017; Efthymiadou et al., 2019; Wouters 
et al., 2015). Given the limited consideration of value in traditional economic evaluations, 
additional parameters have been included in value assessments; however, this is often done in 
a non-systematic or ad-hoc manner, which may impact the transparency of decision-making 
processes (Angelis et al., 2018) and lead to inconsistencies in drug coverage decisions. 
A growing body of literature is increasingly debating the use of highly expensive new 
drugs, which are perceived to bring marginal added clinical benefit on the grounds of poor 
value-for-money and high budget impact (Nadler et al., 2006; Shih et al., 2013; Sulmasy & 
Moy, 2014). Rising drug prices and the need to understand the importance of different 
evaluation criteria have catalysed the generation of numerous “value frameworks” aiming to 
inform payers, clinicians and patients on the assessment of new medicines, required for 
making coverage and treatment selection decisions (Anderson et al., 2014; Bach, 2015; 
Cherny et al., 2015; Schnipper et al., 2015). Although this is an important step towards a more 
inclusive value-based assessment approach (Malone et al., 2016), aspects of these frameworks 
*Revised manuscript (clean) EXCLUDING AUTHOR DETAILS
Click here to view linked References
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may be based on weak or ad hoc methodologies, which could potentially result in misleading 
recommendations or decisions (Angelis & Kanavos, 2016a).  
In response to some of the concerns raised above, multiple criteria decision analysis 
(MCDA) has emerged as an alternative to traditional economic evaluation techniques with the 
prospects of addressing some of their limitations in Health Technology Assessment (HTA) 
(Angelis et al., 2016; NJ Devlin & Sussex, 2011; Mireille M. Goetghebeur et al., 2008; 
Kanavos & Angelis, 2013; Marsh et al., 2014; Radaelli et al., 2014; J Sussex et al., 2013b; 
Thokala, 2011), but also for eliciting stakeholder preferences and faciltating treatment 
selection (Danner et al., 2011; Ijzerman et al., 2008; Tervonen et al., 2015). A number of 
MCDA empirical studies have explored the question of value in a number of therapeutic 
areas, often simulating hypothetical HTA settings (Angelis et al., 2017; M. M. Goetghebeur et 
al., 2010; Jon Sussex et al., 2013a; Wagner et al., 2017). However, very few studies have 
explored the same issue by eliciting the preferences of HTA agencies and sitting decision 
makers and only in single-case exercises  (Angelis, 2018; Jaramillo et al., 2016; Tony et al., 
2011). To the best of our knowledge, no study has ever compared the value preferences of 
decision-makers across multiple settings using a full MCDA methodology. 
By engaging HTA agencies and health insurance organisations in four EU Member 
States, we applied the Advance Value Framework (AVF), a recently developed multi-criteria 
value framework applicable to HTA (Angelis & Kanavos, 2016b; Angelis & Kanavos, 2017), 
to assess the value of a number of treatment options indicated for metastatic castrate resistant 
prostate cancer (mCRPC) following first line chemotherapy. This indication was selected 
because of its high disease burden and the availability of several new and expensive biologic 
drugs, making it a highly relevant appraisal topic for several HTA agencies. 
This is to our knowledge the first cross-country, complete MCDA pilot exercise, 
eliciting value preferences of sitting decision-makers from different HTA agencies for the 
same drug treatments while considering identical sets of evidence. The two main research 
questions of the study relate to testing the feasibility of this MCDA methodology for HTA 
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decision-makers, and to observing any differences in their value perceptions as reflected 
through the consistency of drugs’ value rankings, including value trade-offs.  
 
Methods 
Methodological Framework  
An MCDA approach based on Multi-Attribute Value Theory (MAVT) was adopted (Keeney 
& Raiffa, 1993; von Winterfeldt & Edwards, 1986), involving the phases of problem 
structuring, model building, model assessment, model appraisal, and development of action 
plans (Angelis & Kanavos, 2016b). A series of facilitated workshops were organised taking 
the form of decision conferences (Phillips, 2007), adopting a facilitated decision analysis 
modelling approach (Franco & Montibeller, 2010b; Phillips & Phillips, 1993), in 
collaboration with decision-makers from four HTA agencies and health insurance bodies: the 
Dental and Pharmaceutical Benefits Agency (TLV, Sweden), the Andalusian Health 
Technology Assessment Agency (AETSA, Spain), the Agency for Health Technology 
Assessment and Tariff System (AOTMiT, Poland), and the National Health Insurance Agency 
(INAMI-RIZIV, Belgium). The agencies in these countries were selected in order to represent 
a set of organisations with diferent governance structure (arms’ length HTA agency, e.g. 
AOTMiT, TLV and AETSA, vs integrated HTA function, e.g. INAMI-RIZIV) and 
responsibilities (regulatory, e.g. TLV, vs advisory AOTMiT and AETSA). This research was 
undertaken in the context of Advance-HTA, an EU-funded project focusing on HTA 
methodological advancements (London School of Economics, 2019), and all four HTA 
organisations were contacted to participate under the auspices of the project. 
The methodological process used in terms of the design, implementation and analysis, 
is aligned with the ISPOR good practice guidelines on the use of MCDA for health care 
decisions (Marsh et al., 2016).  
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Problem structuring: Clinical Practice and Scope of the Exercise  
Prostate cancer is the second most commonly diagnosed cancer in men globally and the most 
frequently diagnosed cancer among men in developed countries; it is the fifth leading cause of 
cancer death globally (Torre, 2015). Death rates have been decreasing in the majority of 
developed countries, which has mainly been attributed to improved treatment and/or early 
detection (Center et al., 2012). 
The decision context relates to the assessment of value of second line treatments for 
mCRPC based on the approved European Medicines Agency (EMA) indication (EMA, 
2016a, b, c), the subsequently defined scope of Technology Appraisals (TAs) by a number of 
HTA agencies and the ESMO guidelines (Horwich et al., 2013; NICE, 2012a, b, 2014; TLV, 
2014, 2015a).     
The first treatment to demonstrate a survival benefit for mCRPC patients was 
docetaxel chemotherapy in combination with prednisolone when compared to mitoxantrone in 
combination with prednisolone (Berthold et al., 2008; Tannock et al., 2004). Subsequently, 
new therapeutic agents have been tested in the post-chemotherapy setting with considerable 
success. Abiraterone, a steroid synthesis inhibitor, in combination with prednisolone showed a 
3.9-month improvement in survival compared to prednisolone alone in patients pre-treated 
with docetaxel (14.8 vs 10.9 months, HR 0.65, p<0.001) (de Bono et al., 2011). Similarly, 
enzalutamide, an androgen receptor antagonist, showed a 4.8-month improvement in survival 
(18.4 vs 13.6 months, HR 0.63, p<0.001) compared to placebo alone in the same patient 
group (Scher et al., 2012). Cross-resistance appears to exist between abiraterone and 
enzalutamide meaning that patients are unlikely to derive clinical benefit by switching from 
one to the other agent (Bianchini et al., 2014; Loriot et al., 2013). The third agent that is 
widely used following progression on docetaxel is cabazitaxel, a taxane chemotherapy. 
Cabazitaxel led to an overall survival (OS) benefit of 2.4 months (15.1 vs 12.7 months, HR 
0.70, p<0.0001) compared to mitoxantrone (de Bono et al., 2010). Given this therapeutic 
landscape for patients with mCRPC who have progressed on first line docetaxel 
chemotherapy, characterised by an availability of different treatments and the apparent cross-
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resistance between some of them, we adopt post-chemotherapy mCRPC as the decision 
context for the application of the AVF methodology.  
 
Model Building: Advance Value Tree adaptation, treatments compared and reference levels 
The model building phase comprised a number of tasks, notably the Advance Value Tree 
adaptation for mCRPC, the consideration of alternative drug treatments and the respective 
evidence, and the definition of criteria attributes and the associated ranges, all of which are 
discussed below. Detailed discussion on the rationale of each criterion and their value scales 
can be found elsewhere (Angelis & Kanavos, 2017; Angelis et al., 2017).  
 
(a) Adaptation of the Advance Value Tree for Metastatic Prostate Cancer  
At the core of AVF lies the Advance Value Tree, a hierarchical structure of evaluation criteria 
taking the form of a generic value tree reflecting value concerns of HTA experts and decision-
makers for new medicines (Angelis & Kanavos, 2017). The Advance Value Tree consists of 
five criteria domains, aiming to capture the essential value attributes of new medicines in the 
HTA context under a prescriptive decision-aid approach. These are divided into (a) Burden of 
Disease (BoD); (b) Therapeutic Benefit (THE); (c) Safety Profile (SAF); (d) Innovation Level 
(INN); and (e) Socioeconomic Impact (SOC), summarised by the following value function:  
  
                                 (1) 
 
The Advance Value Tree was adapted into a disease-specific mCRPC value model using a 
bottom-up approach by comparing the characteristics of the specific drugs evaluated (Franco 
& Montibeller, 2010a). In consultation with a specialist medical oncologist (co-author of the 
paper), the generic evaluation criteria were converted into disease-specific criteria, while 
adhering to required criteria properties such as non-redundancy and preferential-independence 
(Keeney, 1992), to ensure methodological robustness and an adequate value model rooted in 
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decision theory. Based on the above, a preliminary mCRPC-specific value tree was produced 
with four criteria domains and a total of 18 criteria, each operationalised by an attribute, i.e. 
performance indicator, as shown in Figure 1. The BoD domain was not considered in the 
adaptation process on the grounds of conciseness, as all drugs were indicated for the same 
indication which would have identical BoD. 
Criteria definitions (together with their consideration in each jurisdiction and their 
rankings) are provided in Table 1.  The preliminary version of the mCRPC value tree was 
subsequently validated by decision conference participants, in line with a “socio-technical” 
approach, a constructive decision-aid process allowing groups of participants to interact with 
and learn from each other (Bana e Costa & Beinat, 2005).  
 
<Figure 1 about here> 
 
(b)  Alternative Treatments Compared and Evidence Considered  
The alternative drug options assessed in the exercise were cabazitaxel in combination with 
prednisolone, abiraterone in combination with prednisolone and enzalutamide monotherapy.  
The key evidence sources used to assess their performance included (a) the peer review 
publications concerning the pivotal clinical trials of the alternative treatment options that were 
considered for their licencing by the EMA (de Bono et al., 2011; de Bono et al., 2010; Fizazi 
et al., 2012; Scher et al., 2012); (b) the Product Information sections of EMA’s European 
Public Assessment Reports (EPAR) (Annex I and III) (EMA, 2016a, b, c); (c) the Anatomical 
Therapeutic Chemical (ATC) classification system indexes available through the portal of the 
WHO Collaborating Centre for Drug Statistics Methodology (World Health Organisation 
Collaborating Centre, 2016); and (d) the US National Library of Medicine clinical trials 
database (NIH, 2016). Additional sources of evidence included national sources (BNF, 2015; 
Connock et al., 2011; NICE, 2012a, b, 2014; Riemsa et al., 2013) and other peer review 
literature (Burström et al., 2001; Collins et al., 2007; Kearns et al., 2013; Sullivan et al., 
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2007), which was relevant to the study indication. Sources of evidence used relating to the 
performance of drugs across evaluation criteria are shown in Appendix Table A1, alongside 
additional information on the evidence considered. 
 
(c) Options Performance and References Levels  
By considering the performance of the alternative drug options across the value scales, 
“lower” (x_l) and “higher” (x_h) reference levels were defined to serve as benchmarks for the 
value scores of 0 and 100 respectively, acting as value anchors for constructing value 
functions and eliciting their relative weights (Bana e Costa & Vansnick, 1999; Keeney, 1982). 
The “lower” reference levels denoted a less preferred state reflecting a “satisfactory” 
performance level, whereas the “higher” reference levels denoted a more preferred state 
reflecting an “ideal” performance level.  
The reference levels for the clinical attributes informing the Therapeutic and Safety 
criteria domains, were defined in consultation with the clinical oncologist (co-author of the 
paper). In principle, the rationale involved adopting the Best Supportive Care (BSC) 
performance as a “satisfactory” reference level, with a hypothetical 20% improvement of the 
best available performance acting as the “ideal” reference level (e.g. ‘overall survival’), or, 
alternatively, the best possible limit of the performance scale acting as an “ideal” level in 
cases where this was naturally restricted (e.g. ‘treatment discontinuation’). The 20% 
hypothetical performance improvement was selected because it was perceived to be a 
realistically plausible scenario for future treatment options. By considering the performance 
of best available option(s) among the treatments evaluated and accounting for plausible 
performance improvement in the near future, the value scale essentially reflected 
characteristics of a “global” scale to account for the performance of future options not 
captured in the exercise, i.e. what is best plausible (Belton & Stewart, 2002). Where a BSC 
performance was not meaningful to act as a “lower” reference level, then the lowest (i.e. 
worst) possible limit of the performance scale was adopted (e.g. ‘Phase 3’), or, alternatively, 
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20% lower than the lowest performing option was used (e.g. ‘medical costs impact’). An 
exception to the above was the ‘health related quality of life’ (HRQoL) attribute for which the 
stable disease state’s utility score was adopted as the “lower” level and the general population 
utility score was used as the “higher” level. 
The emerging partial value function scores of the drugs for each criterion can take 
negative values or values higher than 100 where v(xlower) = 0 and v(xhigher) = 100, essentially 
by conducting a positive linear transformation.  “Lower” and “higher” reference levels for all 
attributes at the pre-decision conference stage and the basis of their selection are outlined in 
Appendix Table A2. A matrix listing the performance of drug options across the final 
attributes that were considered in the decision conferences, together with their reference 
levels, is shown in Table 2. 
 
Model Assessment and Appraisal: Decision conferences, MCDA technique and cost 
calculation 
The model assessment and appraisal phases comprised the tasks of conducting the decision 
conferences, the application of the MCDA technique for the elicitation of value preferences 
and cost calculation(s). These are discussed below. 
 
(a) Decision conferences 
Model assessment and model appraisal took place through a series of decision conferences 
(Phillips, 2007), taking the form of facilitated workshops with the participation of decision-
makers, including assessors and national experts, all of whom were affiliated with the four 
study HTA organisations, either as members of staff or visiting external experts (their 
difference being in full-time employment versus part-time or visiting capacity employment). 
For the purposes of this study, they were both regarded as “decision-makers”, given their 
influence on methodological development within the agencies and on the decision outcomes 
of the appraisals. Across the four countries, between four (for the case of TLV) and 13 (for 
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the case of AOTMiT) participants were involved, typically comprising health care 
professionals (clinicians, pharmacists), HTA methodology experts (health economists, 
statisticians, HTA agency directors) and decision-makers (members of HTA appraisal 
committees, representatives from insurance funds and the national medicines agencies). 
Background material introducing the scope of the exercise in more detail was sent to the 
participants one week before each decision conference. Decision conferences were hosted at 
the head offices of the different HTA organisations between June 2015 and April 2016: 
Stockholm (TLV), Seville (AETSA), Warsaw (AOTMiT), and Brussels (INAMI-RIZIV).  
The lead author acted as an impartial facilitator, assisted the groups’ interactions and 
guided participants through the decision problem using the preliminary version of the 
mCRPC-specific value tree (Figure 1) and the relevant data. This acted as the model’s starting 
point, based on which value judgements and preferences were elicited at the start of each 
decision conference while seeking group interaction and agreement (Franco & Montibeller, 
2010b; Phillips, 1984; Phillips & Bana e Costa, 2007; Schein, 1999). The Appendix provides 
more information on the decision conferences.  
 
(b) MCDA Technique 
AVF adopts a value measurement MCDA methodology making use of a simple additive (i.e. 
linear, weighted average) value model for the aggregation of scores and weights (Angelis & 
Kanavos, 2017). This assumes preference independence between the different criteria, with 
overall value V(.) of an option a defined by the equation below (Keeney, 1992; von 
Winterfeldt & Edwards, 1986): 
 
                                                        (2) 
 
Where m is the number of evaluation criteria, wi vi(a) is the weighted partial value function of 
evaluation criterion i for treatment a, and V(a) is the overall value of a treatment a. V(.) is 
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therefore is an overall value function based on multi-attribute value theory (Keeney & Raiffa, 
1993).  
A value function associated with each attribute, converting the treatment performance 
on the attribute range to a value scale, was elicited from the participants during the decision 
conferences using the Measuring Attractiveness by a Categorical Based Evaluation Technique 
(MACBETH) questioning protocol and the M-MACBETH software (Bana e Costa & 
Vansnick, 1999). This protocol requires pairwise comparisons where qualitative judgements 
about the difference of value between different pairs of attribute levels (i.e. difference in value 
between x and y units on a criterion) are expressed using seven qualitative categories (i.e. no 
difference, very weak difference, weak difference, moderate difference, strong difference, 
very strong difference, or extreme difference) (Bana E Costa et al., 2012; Bana e Costa & 
Vansnick, 1994). MACBETH provides a constructive and user-friendly approach to generate 
a cardinal (interval) value scale based on the input of these qualitative pair-wise judgements, 
which are then converted into value scores via an optimization algorithm (Bana e Costa et al., 
2016b); this approach has been widely used as a decision support tool (Bana e Costa et al., 
2014; Bana e Costa et al., 2002; Bana e Costa & Oliveira, 2012; Bana e Costa & Vansnick, 
1997). 
Weights for a multi-attribute value function should be elicited considering the range 
of each attribute and the value of a “swing” between two reference levels. The weights are 
scaling constants that convert partial value scores into overall value scores that must reflect 
value trade-offs and, therefore, should not be interpreted as measurements of ‘direct 
importance’. An indirect (qualitative) swing weighting technique was applied to elicit relative 
criteria weights by first ordering the swings of each attribute and then valuing their 
differences using the MACBETH qualitative categories (Bana E Costa et al., 2012). 
The above MACBETH-based scoring and weighting techniques were operationalised 
using the software M-MACBETH, (Bana e Costa & Vansnick, 1999). The software automates 
the additive aggregation of preference value scores and weights in order to derive overall 
weighted preference value (WPV) scores and also allows for sensitivity analysis on the 
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criteria weights. The software also enables the use of visual graphics to build a model of 
values, acting as a facilitation tool to inform both the design and the evaluation phases of the 
methodological framework (Bana e Costa et al., 2016a; Bana e Costa & Vansnick, 1999; 
Bana e Costa et al., 1999). More information regarding the technical details of MACBETH is 
available in the Appendix. 
 
(c) Cost Calculation 
UK list prices at ex-factory level were used as found in BNF (BNF, 2015) as a neutral 
benchmark in order to allow the measurement of cost(s) in a common unit across all study 
settings, so that overall WPV scores can then be viewed against the same cost denominator to 
produce comparable cost-value ratios. Access to confidential prices through risk sharing 
agreements was not possible. Information on the recommended dosages and treatment 
durations were sourced from the peer review publications of the pivotal trials and respective 
EPARs from EMA (de Bono et al., 2011; de Bono et al., 2010; EMA, 2016a, b, c; Scher et al., 
2012). Drug administration costs for cabazitaxel were kept consistent with the respective 
NICE TA (NICE, 2012b), whereas for abiraterone and enzaluatmide these costs were not 
applicable as they are orally administered.   
 
Results 
Final Value Trees, Options Performance, Criteria Weights and Value Functions 
Across the four countries, decision conferences were characterised by increased interaction 
and extensive debate between participants, especially in cases where there was disagreement 
about certain values. Because the majority of participants had a shared understanding of the 
decision problem but also a sense of common purpose and commitment to way forward, all of 
which are conditions for good practice in decision conferencing, the deliberative process of 
each decision conference instigated a fruitful discussion and exchange of views around 
different criteria values and relative importance.  
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General consensus was reached among participants in terms of criteria consideration 
and model validation with no major value aspects deemed to be missing. All attributes 
included in each country’s final mCRPC value tree, as emerged following open interaction 
with decision conference participants and their rankings, are shown in Table 1 (schematic 
illustrations of the individual value trees are shown in Appendix Figure A1). The main reason 
for not including a criterion attribute in the value tree was because participants considered it 
was non-fundamental for the evaluation, in all cases of which a zero weight was assigned. 
Most of the criteria attributes that were assigned a zero weight belonged in the Innovation 
Level domain, which comprised the highest number of criteria.  
 
<Table 1 about here> 
 
The performance of the drug options across the different attributes that were 
considered to be fundamental in the model (i.e. weight greater than zero) together with the 
“lower” and “higher” reference levels are shown in Table 2.  
 
<Table 2 about here> 
 
Between 6 (AOTMiT) and 11 (AETSA/INAMI) criteria attributes were included in 
the final value tree of each country, as shown in Table 3. In terms of the different criteria 
domains composition, the Therapeutic Benefit contained between two 
(TLV/AOTMiT/INAMI) and three (AETSA) criteria attributes, the Safety Profile between 
one (AOTMiT) and two (TLV/AETSA/INAMI), the Innovation Level between two 
(TLV/AOTMiT) and six (INAMI), and the Socioeconomic Impact always one.  
 
<Table 3 about here> 
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During the elicitation of the ‘overall survival’ (OS) and/or ‘HRQoL’ criteria value 
functions, it became evident that these criteria attributes might be preference dependent. 
When asking participants to judge the difference in value between different increments in 
attribute performance (either in ‘OS’ or ‘HRQoL’), a request for clarification was raised by 
some of them relating to what level of performance this change was associated with on the 
other criterion attribute. In order to address the plausible preference-dependence observed, we 
combined together the two attributes in an aggregated form. The two criteria attributes were 
combined by multiplying the number of months in ‘OS’ and their EQ-5D utility scores in 
‘HRQoL’ attributes respectively, assuming an equal (i.e. 50%) distribution of stable and 
progressive disease states, essentially deriving quality adjusted life months (QALMs). An 
example of a MACBETH value judgements matrix and its conversion into a value function 
for the case of the ‘OS x HRQoL’ aggregated criterion attribute in QALMs is shown in 
Appendix Figure A2.  
There was a common set of six criteria that were considered as fundamental in all 
countries: (a)  ‘OS x HRQoL’; (b) ‘radiographic tumour progression’ (also known as 
progression free survival (PFS); (c) ‘treatment discontinuation’; (d) ‘delivery posology’; (e) 
‘special instructions’; and (f) ‘medical costs impact’. This common set of criteria comprised 
the complete set of TLV’s value tree (n=6), whereas AOTMIT’s value tree considered 
‘contraindications’ in addition (n=7). Further to these, AETSA’s value tree also considered 
‘PSA response’, ‘ATCL4’, ‘Phase 3’ and ‘marketing authorisation’ (n=11), whereas INAMI’s 
value tree considered the same additional criteria but with ‘Phase 2’ instead of ‘PSA 
response’ (n=11). 
Overall, the different groups of decision conferences’ participants agreed in the 
valuation of performance for the six common attributes that were considered across all four 
countries, as revealed through the elicitation of their value functions. Figure 2 plots the value 
scores of each drug across the six common attributes showing very similar valuations between 
countries.   
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<Figure 2 about here> 
 
The weights of relative importance assigned to the different attributes across the four 
jurisdictions are shown in Figure 3. By taking into account the relative swings of the criteria 
attributes, i.e. the gap between the “lower” and “higher” reference levels, quantitative weights 
were derived for each attribute using M-MACBETH. The ‘OS x HRQoL’ aggregated 
criterion attribute was always assigned the highest relative weight out of 100 ([31,44] for 
INAMI and AETSA, respectively), followed either by ‘treatment discontinuation’ ([17,21] for 
AETSA and TLV, respectively) or ‘medical costs impact’ ([20,30] for INAMI and AOTMiT, 
respectively). Depending on the country, the third-ranked criterion was then either ‘treatment 
discontinuation’ (AOTMiT, INAMI), ‘medical costs impact’ (TLV), or ‘contraindications’ 
(AETSA) and ‘PFS’ was ranked 4th or 5th. ‘Special instructions’, although a fundamental 
criterion across settings, was ranked in the lowest place in 3 out of 4 settings with the 
‘delivery posology’ usually at a higher position, with the exception of TLV where that order 
was reversed. 
 
<Figure 3 about here> 
 
In terms of the total weights assigned across the different criteria domains, the 
Therapeutic Benefit weight ranged from 40% to 54% (for AOTMiT/ INAMI and AETSA, 
respectively), the Safety Profile weight ranged from 20% to 33% (for AOTMiT and TLV, 
respectively), the Innovation Level weight ranged from 7% to 13% (for TLV and INAMI, 
respectively) and the Socioeconomic Impact weight ranged from 8% to 30% (for AETSA and 
AOTMiT, respectively) (Table 3). The above differences in relative weights reflect the 
different priorities of decision-makers, including the number of fundamental objectives being 
considered. 
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Overall Drug Rankings and Value-for-Money Analysis 
With regards to the overall WPV scores shown in Table 4,  enzalutamide consistently yielded 
the highest score across all four countries, always followed by abiraterone and cabazitaxel. 
The overall scores of abiraterone and cabazitaxel were in part influenced by a “negative” 
performance in the ‘treatment discontinuation’ attribute (19% and 18% respectively) which 
lay below the lower reference level of the scale (i.e. 10%), affecting negatively their overall 
value scores.  
A stacked bar plot of the drugs’ overall WPV scores across all settings is shown in 
Figure 4. By using rounded up cost figures for enzalutamide (£24,600), abiraterone (£21,900) 
and cabazitaxel (£23,900, of which £22,190 related to drug cost and the remainder £1,710 to 
administration cost) and dividing them with overall WPV scores, their costs per MCDA value 
unit ranged as follows: (a) enzalutamide: £410 - £501 (for AOTMiT and AETSA, 
respectively); (b) abiraterone: £1,366 - £9,221 (for INAMI and TLV, respectively); and (c) 
cabazitaxel: £2,196 - £6,816 (for INAMI and AOTMiT, respectively) (Table 4).  The overall 
value score of each option was driven by the fundamental objectives considered (i.e. criteria 
influencing the model), the criteria weights which were anchored on reference levels, and the 
shape of value functions which would influence the value scores. 
 
<Table 4 about here> 
 
<Figure 4 about here> 
 
In terms of value-for-money, cabazitaxel was shown to be dominated by abiraterone, 
and was very close to being dominated by enzalutamide (i.e. a difference of £500 based on the 
prices used). Enzalutamide on the other hand was associated with a higher cost (a difference 
of £2,500 based on the prices used) and a higher overall WPV score compared to abiraterone, 
with a difference in score ranging between 40.4 to 52.7 value units (for AETSA and TLV, 
respectively). Cost benefit plots of the different options, using their overall WPV scores 
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versus their purchasing (plus any administration) costs across the four HTA organisations is 
shown in Figure 5.   
 
<Figure 5 about here> 
 
Similarities and differences in value perceptions across settings 
By looking at Table 3 (and Figure 3) of the results, a number of similarities and differences in 
value preferences are observed across the four settings. The largest number of evaluation 
criteria were considered in Andalusia and Belgium (11 each), compared to Sweden and 
Poland (7 and 6, respectively), partly due to a higher number of Innovation Level criteria (5 
and 6, compared to 2 each, respectively). In terms of the relative importance of criteria 
domains, the Therapeutic Benefit cluster consistently ranked first across all settings. The 
Safety Profile cluster was ranked second in three settings (except for Poland, where the 
Socioeconomic Impact cluster ranked higher (30% vs 20%)). The Socioeconomic Impact 
cluster ranked 3rd in Sweden and Belgium but 4th in Andalusia (8%). Finally, the Innovation 
Level cluster ranked 4th in three countries with the exception of Andalusia where it ranked 3rd 
(12%). The low relative importance of the Innovation Level cluster partly justifies why a 
hypothetical change in the final consideration of Innovation Level criteria across the different 
countries does not influence the ranking of the treatments, as described in the next section.  
Despite the observed differences in evaluation criteria considered, the relative criteria 
weights assigned and the elicited value functions, the overall ranking of the treatments 
remained identical across countries (Table 4 and Figure 4) with enzalutamide consistently 
having the highest score, followed by abiraterone and cabazitaxel in all fours settings. 
 
Sensitivity and Robustness Analysis 
Following each decision conference, deterministic sensitivity analysis was conducted to 
address parameter uncertainty on criteria weights. Specifically, changes on baseline weights 
17 
 
were explored to check their possible impact on treatments’ overall value rankings. The 
results of the sensitivity analysis demonstrated that the ranking of the treatments was robust to 
the relative criteria weights across the different settings.    
The most sensitive criterion weight, which could change enzalutamide’s ranking 
order from first to second, was ‘PFS’ in the cases of INAMI and AETSA where a 10.2 and 
11.1 times change (from 8.9% to 90.6% and from 8.0% to 88.5%) respectively, would be 
required for cabazitaxel to rank first and enzalutamide second. In other words, a higher than 
10-times difference on the ‘PFS’ weight would be required for cabazitaxel to outperform 
enzalutamide, with changes of higher order required in other criteria weights for either 
cabazitaxel or abiraterone to rank first, in any of the study settings. Criteria weights were 
more sensitive with regards to the outperformance of abiraterone by cabazitaxel as the 
second-best treatment. Again, the most sensitive weight was for ‘PFS’ in the INAMI and 
AETSA cases, where a 2-times change (from 8.9% to 17.4% and from 8.0% to 16.7% 
respectively) would be needed for cabazitaxel to rank second and abiraterone third. This 
meant that the lowest change across criteria weights needed for an impact on treatment 
rankings to be observed was for the case of PFS with INAMI, where at least a 2-time 
difference was required for abiraterone to be outperformed. For the case of TLV and 
AOTMiT, the most sensitive criterion was treatment discontinuation in which a 2.6 and 3.0 
times change would be needed (from 21.2% to 54.6% and from 20% to 60% respectively) for 
cabazitaxel to rank second-best.  
The final consideration of the Innovation Level criteria cluster was explored in 
greater detail given that their relevance might be disputed. Removing the ‘ATCL4’ criterion 
and any spill-over effect criteria (i.e. ‘Phase-2’, ‘Phase-3’, ‘MA’) from the value tree of 
AETSA and INAMI, and any patient convenience criteria (i.e. ‘delivery posology’, ‘special 
instructions’) from all country value trees would not affect the treatment rankings.  
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Discussion and policy implications 
This study is the first comparative MCDA exercise, utilising the Advance Value Framework 
and engaging sitting HTA decicion-makers across four EU Member States to elicit and 
comprare their preferences in the evaluation of three mCRPC treatments. In doing so, the 
objective was to test the feasibility of MCDA methods for HTA decision-makers and identify 
differences in value perceptions.   
Based on the evidence used, our results showed that the most valuable therapy for second line 
mCRPC was enzalutamide, followed by abiraterone and cabazitaxel. Each treatment was 
assessed and ranked based on their overall WPV scores, reflecting the value of their 
performance against a set of evaluation criteria, weighted against their relative importance. 
These overall scores were based on the value preferences of decision-makers that were 
collected via a decision conference in each setting, yielding a comprehensive and transparent, 
multi-dimensional benefit component. Subsequent consideration of drug costs (purchasing 
and administration) enabled the estimation of value-for-money in the form of “cost-per-unit of 
value” ratios which showed the second-ranked treatment (abiraterone) to dominate the third 
(cabazitaxel).  
It should be noted that the constructed benefit metric excludes the cost of the 
treatments, i.e. the WPV score considers the impact of the technology on medical costs other 
than the purchasing cost of the technology. Therefore, evaluation of the treatments based 
solely on their overall WPV scores might not be appropriately designed to inform an HTA 
decision context that considers the interventions’ incremental cost per incremental benefit, 
but, rather, a value-based approach to reimbursement or pricing negotiation. 
Attempting a comparison of the ranking achieved in this exercise with what has taken 
place in reality might prove challenging, partly because of how the clinical evidence was 
treated in the exercise, but also because it is not publicly known whether and how any of the 
additional value dimensions evaluated in the exercise were considered in the relevant HTA 
decision-making processes. In Sweden, although abiraterone’s ICER vs BSC (manufacturer 
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estimate of SEK820,000/QALY)(TLV, 2015a), was lower compared to enzalutamide’s ICER 
vs BSC (TLV best estimate of SEK1,100,000/QALY)(TLV, 2014), or lower vs enzalutamide 
(SEK800,000/QALY)(TLV, 2015b), TLV assumed that both treatments had the same clinical 
effect and consequently focused on a cost-minimisation approach rather than cost-utility 
analysis, leading to the implementation of a confidential risk sharing agreement (RSA) as part 
of which discounts can be provided based on treatment duration. A similar conclusion was 
reached in Spain, where the Ministry of Health in its Clinical Assessment Report (Informe de 
Posicionamento Terapeutico - IPT) recommended that there is no clinically relevant 
difference between the benefit-risk balance of enzalutamide and abiraterone, and, therefore, 
decisions should be guided based on drug costs (AEMPS, 2015). Pricing and reimbursement 
decisions are then taken by the Interministerial Committee for Pricing and Reimbursement, 
but the final assessment is not publicly available. At regional/hospital level, a group of 
hospital pharmacists conducted a full health (clinical and economic) technology assessment, 
where enzalutamide and abiraterone were considered to be therapeutically equivalent 
(GHEMA, 2016). In Poland, although AOTMiT accepted that some additional clinical effect 
existed for enzalutamide compared to abiraterone (mainly in secondary endpoints), it was not 
found to be cost-effective compared to abiraterone; however, a confidential RSA enabled a 
final positive recommendation by AOTMiT (AOTMiT, 2017). The final decision 
implemented by the Ministry of Health was to reimburse enzalutamide, similarly to the case 
of abiraterone (Obwieszczenie, 2017). In Belgium, following an indirect comparison no 
clinically relevant differences were found in the treatment outcomes of abiraterone versus 
enzalutamide (INAMI, 2019);  eventually, a managed entry agreement (MEA) enabled 
reimbursement.   
Consequently, and based on the evidence used to populate the MCDA model and 
which would inform decision-making, the hypothetical coverage decisions emerging from the 
ranking of the treatments based on their overall WPV scores might have been different. Given 
the higher overall value of enzalutamide compared to abiraterone, a cost minimisation 
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approach or price parity attained between the two, as inferred following the risk sharing 
agreements in place, might not have been justified. 
One reason why our value models make slightly different predictions is because it has 
captured benefits that go beyond the current formal remits of HTA agencies, therefore the 
results should be viewed as ‘proof-of-concept’, for the purposes of testing the performance of 
the methodology.  Furthermore, the decision context addressed in the exercise was a one-off 
evaluation problem within the indication of mCRPC which might contradict the operational 
scope of some HTA agencies and health insurance bodies relating to repeated decisions 
around the reimbursement of drugs across different disease areas.  
The extent to which HTA decision-makers can be relied upon, or not, to reflect 
societal preferences when constructing their value preferences is a very important topic for 
discussion but not aimed to be addressed in this study. Here, we simply elicited decision-
makers’ own preferences without considering whether these might be representative for 
society or not. In reality, evidence in Belgium suggests that health care coverage related 
preferences of decision-makers differ to those of the public (Cleemput et al., 2018), and 
therefore more research would be needed to reveal such discrepancies.   
Overall, the HTA decision-makers that participated in the decision conferences 
provided positive feedback about the potential usefulness of the value framework and the 
MCDA approach in general, raising the prospects of the framework acting as a decision 
support tool in the evaluation of new medicines. According to participants, key advantages of 
the framework included the feasibility to transparently assess the performance of the options 
across a number of explicit evaluation criteria, while allowing the elicitation of value trade-
offs (i.e. their relative importance), and its overall facilitative nature in the construction and 
analysis of group value preferences. Our results are in line with past evidence on a different 
oncology indication (Angelis et al., 2017). 
 
Challenges of MCDA applications in HTA 
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The assessment across 4 settings has offered a number of important insights relating to the 
application of MCDA in HTA and the challenges this represents. In order for any MCDA 
methodology to become a useful tool for HTA decision-makers and serve their needs, certain 
requirements must be met: first, sound methods should be used to ensure technical 
requirements are fulfilled (Keeney & Raiffa, 1993); second, social aspects of the process 
should be treated carefully to ensure various socio-technical requirements are fulfilled 
(Baltussen et al., 2017); and, third, tools and guidelines should be available and tailored for 
the appropriate audience ensuring that best practice requirements are fulfilled (Phillips, 2017).   
Among the first group of technical requirements, one key challenge of MCDA studies 
in HTA relates to the theoretical properties that are required for the evaluation criteria. Due to 
the popularity of using a simple additive (i.e. weighted average) value model, the violation of 
preference-independence is of particular relevance as it might undermine the validity of such 
models and the insights offered by the results (Marsh et al., 2018; Morton, 2017). Evidence 
suggests that preference dependencies might exist between health gain and disease severity 
(Nord et al., 2009), or between OS and HRQoL (Angelis & Kanavos, 2017). The latter also 
featured strongly in this study, where such a preference dependence between OS and HRQoL 
was detected during the decision conferences and, as a result, the two criteria attributes were 
combined into a common aggregated attribute. Beyond combining the two criteria into a 
common aggregated attribute, other more technically complex solutions exist for addressing 
preference dependencies, such as using other functional forms of aggregation for combining 
scores and weights together, such as multiplicative models (Chongtrakul et al., 2005). 
Furthermore, tests for identifying preference dependencies have existed for many years 
(Currim & Sarin, 1984; Keeney, 1992; Rodrigues et al., 2017). 
Other technical challenges relate to the need for evaluation criteria to be non-
overlapping so that there can be no double counting, and that criteria weights are connected to 
the attribute ranges. If either one of these conditions is not satisfied, criteria weights could 
misrepresent decision makers’ true value preferences. Furthermore, a number of cognitive 
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biases may affect value judgments and thus appropriate elicitation protocols and de-biasing 
tools must be employed (Montibeller & Winterfeldt, 2015).    
In order to avoid double-counting, a clear justification of their inclusion is needed, 
which should be on the grounds of addressing the fundamental objectives of the analysis, 
rather than be informed based on the existence of available evidence and data (Keeney, 1992; 
Keeney & Gregory, 2005).  This process could be supported by the use of problem structuring 
tools aiming to distinguish between ‘fundamental objectives’ and ‘means objectives’ (Franco 
& Montibeller, 2010a), as we adopted in this exercise.  
In terms of weighting, asking direct questions for the general importance of criteria 
are known to be one of the most common mistakes when eliciting value trade-offs (Keeney, 
1992; Keeney, 2002). Instead, sound weighting procedures for the assignment of relative 
weights should take place in accordance with the use of explicit lower and higher reference 
levels (Belton & Stewart, 2002; Keeney, 2002), ideally through user-friendly indirect 
technique protocols that can reduce bias, similar to what we aimed for in this exercise through 
the explicit definition of reference levels and the implementation of the qualitative 
(MACBETH) swing weighting technique.   
A further challenge relates to the linking of MCDA results with coverage and 
resource allocation decisions, possibly through the use of specific value thresholds, that can 
reflect the efficiency and opportunity cost of funding decisions (Sculpher et al., 2017). In 
economic evaluation, incremental cost effectiveness ratio (ICER) thresholds are supposed to 
reflect the opportunity cost of the benefit foregone elsewhere in the health care system that 
would have resulted from the coverage of alternative technologies (Claxton et al., 2015).  
Assuming that a QALY-based ICER threshold is accurate, it could be used as a benchmark to 
create an MCDA value threshold by extrapolating the ICER threshold in proportion to how 
much of the MCDA model’s weight is accounted for by non-QALY value components 
(Phelps & Madhavan, 2018). Alternatively, following the generation of a multi-dimensional 
benefit component, purchasing costs could be used to derive treatments’ cost-value ratios to 
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inform the resource allocation decisions assuming a fixed budget (Peacock et al., 2007), 
similar to our approach in this exercise with the calculation of the “cost per unit of value”.  
 
Study limitations  
The study has a number of limitations, both related to the clinical evidence used and the 
MCDA process followed, so results should be interpreted with caution. First, in terms of the 
clinical data used, there was a lack of relative treatment effects; in order to counteract that, 
absolute treatment effects from different clinical trials were used based on the assumption that 
they are directly comparable which might not be accurate even for similar patient populations 
in the studies. As a result, differences in the performance of the options that have been valued 
might in reality not be statistical significant, e.g. in OS. Ideally, one would need indirect 
comparisons or a network meta-analysis (NMA) through a mixed treatment comparison 
(Jansen et al., 2011), therefore, an evidence synthesis step would be required as part of the 
model-building phase; as, for example, in the case of assessing the comparative benefit-risk of 
statins in primary prevention (Tervonen et al., 2015) or second-generation antidepressants 
(van Valkenhoef et al., 2012).  
Second, another clinical evidence related limitation could be that only the treatments’ 
impact on HRQoL of the stable disease state was assessed, because no treatment was assumed 
to have any effect during progression (NICE, 2014). This might not be true for other disease 
indications in which case the relevant HRQoL attribute would have to capture both the stable 
and progressive disease states. 
Third, there are also a number of limitations in terms of the MCDA process adopted: 
one of them relates to the relatively small number of participants in some decision 
conferences, which could reflect a limited representation of perspectives for the purpose of 
informing policy-making. A group size of between seven and 15 participants is known to be 
ideal as they are large enough to represent all major perspectives but small enough to work 
towards agreement, effectively allowing for efficient group processes to emerge while 
preserving individuality, (Phillips & Phillips, 1993).  However, capturing an all-round set of 
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preferences was not among the primary aims of the exercise. The value scale of the treatment 
discontinuation attribute and, more specifically, the “lower” reference level of “10%” could 
be perceived as a limitation because it influenced the negative partial value scores of two 
treatments whose performance was worse. This was the outcome of consultation with an 
oncologist, based on evidence from one of the clinical trials’ placebo-contolled arms, because 
it was believed to better resemble BSC used in practice; although others might have chosen a 
different performance level to define the “lower” reference level, the overall ranking of the 
treatments did not change when altering the lowest reference level to a much less preferred 
hypothetical performance (20% lower than the worst performing option), while keeping the 
weights constant.  
One major advantage in MCDA, is that it can be tailormade to reflect decision-
makers’ needs, by taking into account different fundamental objectives through the 
consideration of a variety of criteria, reflecting their priorities (by eliciting relative weights) 
and representing their preferences (by eliciting value functions). However, it should be 
recognised that the emerging differences that have been described above, prevent the direct 
comparison of overall value scores for alternative options; these would require identical value 
trees (i.e. the same set of criteria, weights and value functions across settings), in addition to 
the same evidence on options performance. The ranking comparisons that we have made in 
this study using ordinal scales reflect these limitations.  
 
Conclusions and implications  
In this study, we tested the application of AVF, a multi-criteria value framework, in 
collaboration with HTA decision-makers in order to deduce its feasibility and compare results 
across settings, in an effort to investigate its potential usefulness and limitations for the 
purposes of HTA. We found that the AVF methodology can act as a valuable decision support 
tool because of the transparent construction of value preferences in a collaborative manner, 
which facilitates the evaluation processes of groups, including the elicitation of value 
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preferences and trade-offs. Although we observed setting-specific differences in value 
perceptions, the rankings of drugs remained consistent across all countries. Based on the 
evidence used in the exercise, a coverage decision using this method would have pointed 
towards a different recommendation denoting differences in value between the first two 
treatments, in contrast with the cost minimisation approach adopted or the price parity 
attained between the two in real life.  
Despite a number of limitations relating to data and process issues and the existence 
of broader challenges with the use of MCDA in HTA due to specific methodological 
requirements which would need to be satisfied, the present study has demonstrated that an 
MCDA framework can, in fact, provide meaningful valuations of novel health technologies 
which, in turn, can inform coverage decisions.  
The MCDA methodology adopted enabled participants in the study countries to 
reflect on certain value dimensions and incorporate these more explicitly in the deliberation 
process, supporting its use as a transparent value communication tool. Future research efforts 
could involve similar cross-county case studies, the advancement of MCDA methods and 
their alignment with HTA policy needs, or repeating the study with different participants to 
understand whether similarities and differences identified in this study can be replicated.  
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Appendix  
 
Model Building: Alternative Treatments Compared and Evidence Considered  
The source of evidence used for identifying the performance of options across the evaluation 
criteria is shown in Table A1.  
 
Model Building: Setting Attribute Ranges and Reference Levels 
For the case of clinical therapeutic attributes, “lower” reference levels were based on best 
standard of care (BSC) performance, coming from the median of the respective placebo arm 
of the AFFIRM trial, with the exception of the HRQoL attribute (EQ-5D utility score) that 
was based on the utility of stable disease with no treatment coming from past NICE TAs 
(NICE, 2012a, b). The “higher” reference levels were derived by adding a 20% absolute 
improvement to the performance level of the best performing option, besides for the case of 
the HRQoL attribute (EQ-5D utility score) that was based on the general Swedish population 
(Burström et al., 2001). The rationale was to design a value scale incorporating a “global” 
reference level (Belton & Stewart, 2002), reflecting an “ideal” performance (as proxied by the 
20% improvement in best available performance), corresponding to the 100 anchor level of 
the value scale. This could also offer a flexibility margin to be able to incorporate the 
performance of future improved options within the same elicited value scale. Consequently, 
two reference levels within the attribute range were defined in most cases: i) the “lower” 
reference level (x_l) (i.e. BSC-based satisfactory performance), acting on the same time also 
as the minimum limit of the attribute range (x_*); and ii) the “higher” reference level (x_h) 
(i.e. 20% better than the best performing option), acting on the same time as the maximum 
limit of the attribute range (x^*) to give x_*=x_l ≤ x_h= x^*.  
A similar, but reverse, logic was used for setting the reference levels in the “treatment 
discontinuation” attribute of the safety cluster; the “lower” reference level was defined to be 
equal to the BSC (i.e. placebo) arm of the AFFIRM trial. However, contrary to the logic 
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adopted so far for the therapeutic benefit criteria, the “higher” reference level was not set 
equal to 20% worse than the best performing option (because the lower the performance, the 
higher the value), but rather equal to the minimum, i.e. worst possible, natural limit of the 
attribute scale (i.e. 0%) which was regarded as an “ideal” level. In turn, the minimum limit of 
the scale was derived by worsening the performance of the worst performing treatment option 
by 20%. A similar approach was used for setting the reference levels of the qualitative 
“contraindications” attribute, defining the “higher” reference level  equal to the maximum 
(i.e. most attractive) limit of the attribute scale (i.e. none known contraindications) and the 
“lower” reference level equal to the minimum (i.e. least attractive) limit of the attribute scale.  
For the innovation attributes, the “higher” reference level was set either equal to 20% 
better than the best performing option for the case of natural quantitative attributes (e.g. 
number of new indications for which the technology is investigated in a given clinical 
development stage), or equal to the maximum, i.e. best possible, limit of the scale for the case 
of constructed qualitative attributes (e.g. the existence of any special instructions, the 
technology's relative market entrance in regards to its ATC Level), reflecting a “global” 
versus “local” scaling approach respectively. Given that the BSC performance was irrelevant 
to be used as satisfactory level in the innovation attributes, and any efforts to derive a 
“satisfactory” level would be subjective in nature, the minimum limit of the scale for each 
attribute was used as a “lower” reference level. Therefore the “lower” reference level was 
based on the worst performance plausible as inferred from the lowest possible limit of the 
scales, both for the case of natural quantitative attributes (e.g. 0 number of new indications for 
which the technology is investigated in a given clinical development stage), and the case of 
constructed qualitative attributes (e.g. worst possible combination of special instructions, 5th 
entrance at an ATC level).  
For the socioeconomics attribute (impact on direct costs), the “higher” reference level 
was based on the BSC’s impact on cost (i.e. £0 impact on costs), given that by definition 
impact on costs for all treatment options are incremental to BSC, and the “lower” reference 
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level was derived by adding a 20% absolute increment to the worst performing option (i.e. to 
the one with the biggest impact on costs).  
 “Lower” and “higher” reference levels for all attributes at the pre-workshop stage 
and the basis of their selection are outlined in Table A2 (assuming no impact of luteinizing 
hormone-releasing hormone analogue).  
 
Model Assessment and Appraisal: Decision Conference 
On the day of each decision conference the preliminary model was validated with the 
participants by revising it cluster by cluster through an open discussion, seeking group 
consensus and adopting an iterative and interactive-model-building process where debate was 
encouraged and differences of opinion were actively sought.  
In terms of the decision-aiding methodology used, the lead author acted as an 
impartial facilitator with the aim of enhancing content and process interaction, while 
refraining from contributing to the content of the group’s discussions, essentially guiding the 
group in how to think about the issues but not what to think (Phillips & Bana e Costa, 2007; 
Schein, 1999).  
In terms of facilities, the rooms of the decision conferences had a Π-shaped meeting 
table for all the participants to have direct eye to eye contact, with an overhead projector 
screen and a second protable projector or large TV screen. The M-MACBETH software 
(more information provided in the MCDA Technique section of the main text and below) was 
operated using a laptop, the screen of which was connected to the projector, and the second 
screen was used to show the list of the evaluation criteria together with their “lower” and 
“higher” reference levels. 
The decision conferences took place over a full working day or two half working 
days; in the former case, there was one lunch break and two coffee breaks throughout the day, 
whereas in the latter case only a coffee break took place around the middle of each session. In 
each decision conference, the day started with an overview of the MCDA methodology 
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adopted and the description of the preliminary version of the value tree which was then 
analysed cluster by cluster. At the beginning of each cluster the value tree was validated; the 
various criteria were explained, followed by a group discussion relating to their relevance and 
completeness. As a result of this iterative process, some of the criteria were not included 
because they were perceived as irrelevant or non-fundamental. Schematic illustrations of the 
final versions of the value trees are shown in Figure A1. Then, value functions were elicited 
for the different criteria and relative weights were assigned within the clusters. Finally, 
relative weights were assigned across clusters, enabling the calculation of the options’ overall 
WPV scores.  
 
Model Assessment and Appraisal: MCDA Technique 
MACBETH uses seven semantic categories ranging between “no difference” to “extreme 
difference”, in order to distinguish between the value of different attribute levels. Based on 
these qualitative judgements of difference and, by analysing judgmental inconsistencies, it 
facilitates the move from ordinal preference modeling, a cognitively less demanding 
elicitation of preferences, to a quantitative value function. The approach has evolved through 
the course of theoretical research and real world practical applications, making it an 
interactive decision support system that facilitates decision-makers’ communication. An 
example of the type of questioning being asked would be “What do you judge to be the 
difference of value between x’ and x’’?” where x’ and x’’ are two different attribute levels of 
attribute x, across the plausible range (i.e. x* ≤ x’, x’’ ≤ x*). The value judgements matrix for 
the Overall Survival attribute and their conversion into its value function is provided as an 
example in Figure A2.  
Following the elicitation of value functions, criteria baseline weights can be elicited. 
Questions of direct importance for a criterion such as “How important is a given criterion?” 
are known to be as one of the most common mistakes when making value trade-offs because 
they are assessing them independent of the respective attribute ranges (Keeney, 2002). In 
contrast, indirect weighting technique that assess value trade-offs in tandem with the 
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respective ranges of attributes should be employed. For example, the quantitative swing 
weighting technique asks for judgments of relative value between ‘swings’ (i.e. changes from 
standard lower level x* to higher reference level x* on each xth attribute) taking the form “How 
would you rank the relative importance of the criteria, considering their attributes ranges 
relative to 100 for the highest-ranked criterion considering its range?”. Each swing, i.e. a 
relative change from a lower attribute level to a higher attribute level, is valued between 0 and 
100, with the most valuable swing anchored as 100 (von Winterfeldt & Edwards, 1986). 
Normalised weights are then calculated, as a proportion of each swing weight, so the 
normalised weights summed to 100%. Instead, relative attribute weights were calculated 
using an alternative qualitative swing weighting protocol, by using the MACBETH procedure 
to elicit the differences in attractiveness between the lower and higher reference levels of the 
different attributes, initially at individual level and then at criteria cluster level (i.e. by 
considering multiple attribute swings on the same time) (Bana e Costa et al., 2016b; Bana E 
Costa et al., 2012). 
Finally criteria preference value scores and the respective weights can be combined 
together through an additive aggregation approach as described in equation 2 (if the adequate 
conditions of complete and transitive preferences are met as well as multi-attribute 
preferential independence conditions (von Winterfeldt & Edwards, 1986)).   
The M-MACBETH software automatically performs consistency checking between 
the qualitative judgements expressed, and in addition a second consistency check was 
manually performed by the author to validate the cardinality, i.e. interval nature, of the 
emerging value scale. This was done by comparing the sizes of the intervals between the 
proposed scores and inviting participants to adjust them if necessary (Fasolo & Bana e Costa, 
2014), a requirement which is essential for the application of simple additive value models. 
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Table 1: Criteria definitions, their consideration in each jurisdiction and their ranking  
Criteria Sub-
Domain 
Evaluation 
criteria  
Definition 
Country (competent HTA organisation) 
Belgium 
(INAMI/RIZIV) 
 
Poland 
(AOTMiT) 
Andalusia 
(AETSA) 
Sweden 
(TLV) 
Criteria Domain 1: Therapeutic Benefit 
Direct endpoints 
Overall survival x 
Health related quality 
of life* 
The median time from treatment randomisation to 
death adjusted for the mean health related quality 
of life using the EQ-5D utility score  
(1st) (1st) (1st) (1st) 
Indirect endpoints 
Radiographic tumour 
progression 
The median survival time on which patients have not 
experienced disease progression (using RECIST 
criteria) 
(5th) (5th) (4th) (5th) 
PSA response 
The proportion of patients having a ≥50% reduction 
in PSA     
(8th)  
Criteria Domain 2: Safety Profile 
Tolerability 
Treatment 
discontinuation 
The proportion of patients discontinuing treatment 
due to adverse events 
(3rd) (3rd) (2nd) (2nd) 
Contra-indications & 
warnings 
Contra-indications 
The existence of any type of contra-indication 
accompanying the treatment 
(4th)  (3rd) (4th) 
Criteria Domain 3: Innovation Level 
Type and timing of 
innovation 
ATC Level 1 
The technology's relative market entrance in regards 
to its ATC Level 1 (Anatomical) 
    
ATC Level 2 
The technology's relative market entrance in regards 
to its ATC Level 2 (Therapeutic) 
    
ATC Level 3 
The technology's relative market entrance in regards 
to its ATC Level 3 (Pharmacological) 
    
ATC Level 4 
The technology's relative market entrance in regards 
to its ATC Level 4 (Chemical) 
(6th)  (10th)  
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ATC Level 5 
The technology's relative market entrance in regards 
to its ATC  Level 5 (Molecular) 
    
Spill-over effect 
Phase 1 
The number of new indications for which the 
technology is investigated in  Phase 1 clinical trials 
    
Phase 2 
The number of new indications for which the 
technology is investigated in  Phase 2 clinical trials 
(8th)    
Phase 3 
The number of new indications for which the 
technology is investigated in  Phase 2 clinical trials 
(9th)  (9th)  
Marketing 
authorisation 
The number of new indications that the technology 
has gained an approval for at the stage of marketing 
authorisation 
(10th)  (7th)  
Patient convenience 
Delivery posology 
The combination of the delivery system (RoA and 
dosage form) with the posology (frequency of dosing 
and duration of administration) of the treatment 
(7th) (4th) (6th) (7th) 
Special instructions 
The existence of any special instructions 
accompanying the administration of the treatment 
(11th) (6th) (11th) (6th) 
Criteria Domain 4: Socio-Economic Impact 
 
 
Direct costs 
Medical costs impact 
The impact of the technology on direct medical costs 
excluding the purchasing costs of the technology 
(2nd) (2nd) (5th) (3rd) 
Notes: *: Aggregation between OS and HRQoL criteria took place due to preference-dependence leading to a combined criterion; PSA= prostate-specific 
antigen; ATC=Anatomical Therapeutic Chemical classification system; RoA=Route of Administration. 
Source: The authors, based on DCs in Andalusia/Spain, Belgium, Poland and Sweden. 
 
 
42 
 
Table 2: Performance matrix and reference levels considered across the final criteria attributes  
Criterion name Attribute metric Lower level Abiraterone Cabazitaxel Enzalutamide Higher level 
Overall survival (OS)* Months 13.6 15.8 15.1 18.4 22.1 
Health Related Quality of Life 
(HRQoL), stable disease* 
Utility (EQ-5D) 0.72 0.76 0.76*** 0.76 0.82 
Health Related Quality of Life 
(HRQoL), progressive disease* 
Utility (EQ-5D) 0.64 0.64 0.64 0.64 0.82 
OS X HRQoL** 
Quality adjusted life 
months (QALMs) 
9.2 11 10.5 12.8 18.1 
Radiographic tumour progression, 
i.e. progression free survival (PFS) 
 
Months 2.9 5.6 8.8 8.3 10.6 
PSA response % of patients 1.5 29.5 39.2 54 64.8 
Treatment discontinuation 
 
% of patients 10 19 18 8 0 
Contra-indication(s) 
Type of contra- 
indication 
hyp + hep imp + 
low neut 
hyp + hep imp 
hyp + hep imp + 
low neut 
hyp None 
ATC Level 4, i.e. chemical 
mechanism of action 
Relative market entrance 5
th
 2
nd
 2
nd
 1
st
 1
st
 
Phase 2 Number of new indications 0 1 13 4 16 
Phase 3 Number of new indications 0 1 2 0 2 
Marketing authorisation Number of new indications 0 0 0 0 1 
Delivery posology 
Type of delivery system & 
posology combinations 
Oral, daily - one 
off + IV, every 3 
weeks - 1 hr 
Oral,  
daily - one off 
Oral, daily - one 
off + IV, every 3 
weeks - 1 hr 
Oral,  
daily - one off 
Oral,  
daily - one off 
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Special instructions 
Type(s) of special 
instructions 
Concomitant 
and/or pre- med 
+ no food 
Concomitant 
and/or pre- 
med + no food 
Concomitant 
and/or pre- med  
None None 
Medical costs impact 
 
GBP 10,000 5,750 7,992 567 0 
Notes: * Used for the calculation of the quality adjusted life months (QALMs) attribute of the aggregated OS x HRQoL criterion; ** Calculated assuming an 
equal 50% split in time duration between the stable disease and progressive disease states in HRQoL; *** Used the same score of the other two options as 
data not available; hyp = hypersensitivity; hep imp = hepatic impairment; low neut = low neutrophil count.  
Source: The authors from the literature. 
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Table 3: Number of criteria attributes per cluster, relative weights per criteria cluster and their ranking across the four HTA settings. 
 
  
Sweden  
(TLV) 
Andalusia  
(AETSA) 
Poland 
 (AOTMiT) 
Belgium 
 (INAMI-RIZIV) 
HTA Agency/  
Criteria Clusters 
Criteria 
numbers 
Criteria 
weights 
Criteria 
ranking 
Criteria 
numbers 
Criteria 
weights 
Criteria 
ranking 
Criteria 
numbers 
Criteria 
weights 
Criteria 
ranking 
Criteria 
numbers 
Criteria 
weights 
Criteria 
ranking 
Therapeutic Benefit 2 44.5 1
st
  3 54.3 1
st
 2 40.0 1
st
 2 40.0 1
st
 
Safety Profile 2 33.3 2
nd
 2 26.0 2
nd
 1 20.0 3
rd
 2 26.7 2
nd
 
Innovation Level 2 7.4 4
th
 5 11.8 3
rd
 2 10.0 4
th
 6 13.3 4
th
 
Socioeconomic Impact 1 14.8 3
rd
 1 7.9 4
th
 1 30.0 2
nd
 1 20.0 3
rd
 
Total 7 100   11 100   6 100   11 100   
 
Source: The authors based on input from decision conferences. 
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Table 4: Overall weighted preference value (WPV) scores, costs and costs per unit of value across the four HTA settings.  
 
Treatments/  
HTA agency 
Enzalutamide Abiraterone Cabazitaxel 
  
Overall WPV 
score 
Ranking per 
country 
Overall WPV 
score 
Ranking per 
country 
Overall WPV 
score 
Ranking per 
country 
Sweden (TLV) 55.1 1
st
  2.4 2
nd
  -3.4 3
rd
  
Andalusia (AETSA) 49.1 1
st
  8.8 2
nd
  4.4 3
rd
  
Poland (AOTMiT) 59.9 1
st
  12.1 2
nd
  3.5 3
rd
  
Belgium (INAMI-RIZIV) 58.6 1
st
  16.0 2
nd
  10.9 3
rd
  
Costs (£) 24,600 21,900 23,900 
  
Cost per unit 
of value 
Ranking per 
country 
Cost per unit of 
value 
Ranking per 
country 
Cost per unit of 
value 
Ranking per 
country 
Sweden (TLV) 447 1
st
  9,221 2
nd
  N/A 3
rd
  
Andalusia (AETSA) 501 1
st
  2,496 2
nd
  5,481 3
rd
  
Poland (AOTMiT) 410 1
st
  1,805 2
nd
  6,816 3
rd
  
Belgium (INAMI-RIZIV) 420 1
st
  1,366 2
nd
  2,196 3
rd
  
  
Note: No cost-per-unit of value was calculated because of the negative overall WPV score (i.e. having a worst overall performance compared to the 
performance of the lower reference level), which would produce a negative cost-per-unit of value (£23,900/(-3.4) = -7,072) and would therefore faulty 
“improve” the median figure of the treatment.   
Source: The authors. 
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Figure 1: Preliminary value tree for metastatic prostate cancer (pre-workshop). 
 
 
 
 
Notes: Contra. = Contraindications; MoA = Mechanism of action; HRQoL = Health related quality of 
life; PSA = Prostate-specific Antigen; ATC = Anatomical therapeutic chemical; Image produced using 
the Hiview3 software version 3.2.0.4. 
Source: The authors. 
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Figure 2: Criteria valuation drug profiles. 
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Figure 3: Relative criteria weights stacked bars across the four HTA settings. 
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Figure 4: Stacked bar plot of treatments’ overall weighted preference value scores across the four HTA settings. 
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Figure 5: Cost benefit plots of treatments overall weighted preference value scores versus their purchasing costs across the four HTA settings 
(TLV top left, AETSA top right, AOTMiT, bottom left, INAMI bottom right). 
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Appendix  
Tables and Figures 
 
Figures (NO AUTHOR DETAILS)
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Table A1: Attributes definition and sources of evidence 
Cluster Attribute Definition 
Evidence source 
Abiraterone Cabazitaxel Enzalutamide 
THERAPEUTIC 
BENEFIT 
Overall survival 
The median time from treatment randomisation to death de Bono et al 2011 de Bono et al 2010 Scher et al 2012 
Health related 
quality of life 
Health related quality of life using the EQ-5D score Sullivan et al 2007; 
TA 255; TA259; 
TA316 
N/A – assumed, 
based on Sullivan 
et al 2007; TA 255; 
TA259; TA316 
Sullivan et al 2007; 
TA 255; TA259; 
TA316 
Radiographic 
tumour progression 
The median survival time on which patients have not 
experienced  disease progression (using RECIST criteria) 
de Bono et al 2011 de Bono et al 2010  Scher et al 2012 
PSA response The proportion of patients having a ≥50% reduction in PSA Fizazi et al 2012 de Bono et al 2010 Scher et al 2013 
SAFETY  
PROFILE 
Treatment 
discontinuation 
The proportion of patients discontinuing treatment due to AEs de Bono et al 2011 de Bono et al 2010  Scher et al 2012 
Contra-indications 
The existence of any type of contra-indication accompanying the 
treatment 
EPAR, 
Prescribing info 
EPAR, 
Prescribing info 
EPAR, 
Prescribing info 
INNOVATION 
 LEVEL 
ATC Level 1 
The technology's relative market entrance in regards to its ATC 
Level 1 (Anatomical) 
WHO ATC index WHO ATC index WHO ATC index 
ATC Level 2 
The technology's relative market entrance in regards to its ATC 
Level 2 (Therapeutic) 
WHO ATC index WHO ATC index WHO ATC index 
ATC Level 3 
The technology's relative market entrance in regards to its ATC 
Level 3 (Pharmacological) 
WHO ATC index WHO ATC index WHO ATC index 
ATC Level 4 
The technology's relative market entrance in regards to its ATC 
Level 4 (Chemical) 
WHO ATC index WHO ATC index WHO ATC index 
ATC Level 5 
The technology's relative market entrance in regards to its ATC  
Level 5 (Molecular) 
WHO ATC index WHO ATC index WHO ATC index 
3 
 
Phase 1 
The number of new indications for which the technology is 
investigated in  Phase 1 clinical trials 
ClinicalTrials.gov ClinicalTrials.gov ClinicalTrials.gov 
Phase 2 
The number of new indications for which the technology is 
investigated in  Phase 2 clinical trials 
ClinicalTrials.gov ClinicalTrials.gov ClinicalTrials.gov 
Phase 3 
The number of new indications for which the technology is 
investigated in  Phase 2 clinical trials 
ClinicalTrials.gov ClinicalTrials.gov ClinicalTrials.gov 
Marketing 
authorisation 
The number of new indications that the technology has gained 
an approval for at the stage of marketing authorisation 
ClinicalTrials.gov ClinicalTrials.gov ClinicalTrials.gov 
Delivery posology 
The combination of the delivery system (RoA and dosage form) 
with the posology (frequency of dosing and duration of 
administration) of the treatment 
EPAR,  
Prescribing info 
EPAR,  
Prescribing info 
EPAR,  
Prescribing info 
Special instructions 
The existence of any special instructions accompanying the 
administration of the treatment 
EPAR,  
Prescribing info 
EPAR,  
Prescribing info 
EPAR,  
Prescribing info 
SOCIO-
ECONOMIC 
IMPACT 
Medical costs 
impact 
The impact of the technology on direct medical costs excluding 
the purchasing costs of the technology* 
BNF 69,  
Prescribing info, 
Connock et al 2011, 
Riemsa et al 2013, 
TA259 
BNF 69, Prescribing 
info, de Bono et al 
2010, TA255 
BNF 69, TA316 
Notes: * These costs include i) concomitant medications, ii) outpatient visits, diagnostic/laboratory tests, hospitalisations and other monitoring costs 
(including management AEs), and iii) terminal care. 
 
 
Source: The authors.
4 
 
 
Table A2: Pre-decision conference attribute reference levels and basis of selection 
Cluster Attribute name Attribute metric Lower level Basis Higher level Basis 
THERAPEUTIC 
BENEFIT 
Overall survival months 13.6 Best supportive care 
(BSC) 
22.1 20% higher than the best 
performing option 
Health related 
quality of life 
utility (EQ-5D) 0.72 Utility used for stable 
disease  
0.82 Utility scores of general 
population 
Radiographic tumour 
progression  
months 2.9 BSC 10.6 20% higher than the best 
performing option 
PSA response % patients 1.5 BSC 64.8 20% higher than the best 
performing option 
SAFETY  
PROFILE 
Treatment 
discontinuation (% of 
patients) 
% patients 10 BSC 0 Highest possible limit of 
the scale 
Contra-indications types of contra- 
indications 
Hypersensitivity + 
hepatic impairment + 
low neutrophil counts 
Lowest possible limit of 
the scale  
None known 
contraindications 
Highest possible limit of 
the scale 
INNOVATION  
LEVEL 
ATC Level 1 relative market 
entrance 
5
th
 Lowest possible limit of 
the scale 
1st Highest possible limit of 
the scale 
ATC Level 2 relative market 
entrance 
5
th
 Lowest possible limit of 
the scale 
1st Highest possible limit of 
the scale 
ATC Level 3 relative market 
entrance 
5
th
 Lowest posisble limit of 
the scale 
1st Highest possible limit of 
the scale 
ATC Level 4 relative market 
entrance 
5
th
 Lowest possible limit of 
the scale 
1st Highest possible limit of 
the scale 
ATC Level 5 relative market 
entrance 
5
th
 Lowest possible limit of 
the scale 
1st Highest possible limit of 
the scale 
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Phase 1 number of new 
indications 
0 Lowest possible limit of 
the scale 
10 20% higher than the best 
performing option 
Phase 2 number of new 
indications 
0 Lowest possible limit of 
the scale 
16 20% higher than the best 
performing option 
Phase 3 number of new 
indications 
0 Lowest possible limit of 
the scale 
2 20% higher than the best 
performing option 
Marketing 
authorisation 
number of new 
indications 
0 Lowest possible limit of 
the scale 
1 20% higher than the best 
performing option 
Delivery Posology types of delivery 
system & posology 
combinations 
Oral, every day - one 
off + IV, every 3 weeks 
- 1 hour* 
Lowest possible limit of 
the scale 
Oral, every day - one 
off* 
Highest possible limit of 
the scale 
Special instructions types of special 
instructions 
No food + 
concomitant and/or 
pre-medication* 
Lowest possible limit of 
the scale 
None* Highest possible limit of 
the scale 
SOCIO-
ECONOMIC 
IMPACT 
Medical costs impact GBP 10,000 20% higher than the 
worst performing 
option (rounded up) 
0 BSC 
Note: * Assuming no impact on Luteinizing hormone-releasing hormone (LHRH) analogue. 
Source: The authors based on the literature. 
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Figure A1: Final value trees for metastatic prostate cancer across the four HTA agencies*  
TLV          AOTMIT  
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* Images produced using the M-MACBETH (beta) software version 3.0.0
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Figure A2: Example of value judgements matrix for the “Overall Survival x HRQoL” 
attribute measured in quality adjusted life months (QALMs) and its conversion into value 
functions (from the AOTMiT decision conference). 
 
 *Image produced using the M-MACBETH (beta) software version 3.0.0 
Caption: In the Overall Survival x HRQoL attribute example, measured in quality adjusted life 
months (QALMs), the question asked was the following: “What do you judge to be the difference of 
value between 9.2 and 18.1 QALMs? No difference, very weak, weak, moderate, strong, very strong, or 
extreme?” Once a decision was reached (by consensus or majority voting), the next question came 
along: “What do you judge to be the difference of value between 12.2 and 18.1 months QALMs? No 
difference, very weak, weak, moderate, strong, very strong, or extreme?” The same process was 
followed until value judgments for all the different combinations of attribute levels were elicited, filling 
in the different rows from the right-hand side (i.e. lower range) to the left-hand side (i.e. higher range). 
Ethics approval: 
Ethics approval is not required for this paper as no personal or sensitive data from human 
subjects were collected. 
*Ethics approval/Statement EA not required
